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Speaker abstracts
Symposium I: Molecular genetics, phenotypes for
prognosis and response to treatments
S1
The role of gene expression profiling by microarray
analysis for prognostic classification of breast cancer
MJ van de Vijver
Department of Pathology, Netherlands Cancer Institute, Amsterdam,
The Netherlands
Breast Cancer Research 2005, 7(Suppl 1):S1 (DOI 10.1186/bcr1205)
Introduction Prognostic and predictive factors play important roles in
the treatment of breast cancer. Genome-wide monitoring of gene
expression using DNA microarrays makes it possible to study thousands
of genes in a tumour sample in a single experiment. By looking for an
association between the gene expression pattern and tumour behaviour,
it should be possible to identify new prognostic and predictive factors.
Method We used gene expression profiling using two different
microarray platforms: one containing 25,000 oligonucleotide probes
and one containing 18,000 cDNA probes. To obtain prognostic gene
expression profiles, we isolated RNA from tumours from a series of 295
patients younger than 53 years presenting with stage I and II breast
cancer treated at our institute between 1984 and 1993. The
expression of 25,000 genes was assessed, and using various
statistical approaches correlation of gene expression with distant
metastasis-free probability and overall survival was assessed [1-3]. In
addition, we started studies to obtain gene expression profiles
predicting response to specific chemotherapy regimens. Within a
single-institution, randomized phase II trial, patients with locally
advanced breast cancer received six courses of either AC (n = 24) or
AD (n = 24) containing neoadjuvant chemotherapy. Gene expression
profiles for 18,000 genes were generated from core needle biopsies
obtained before treatment and correlated with the response of the
primary tumour to the chemotherapy administered [4]. Additionally,
pretreatment gene expression profiles were compared with those in
tumours remaining after chemotherapy.
Results We previously identified a 70-gene expression profile
associated with increased risk for developing distant metastases within
5 years [1,2]. More recently, we studied a Wound Signature in these
same tumors [3]. By combining the 70-gene expression profile to
subdivide the tumours into ‘good prognosis’ and ‘poor prognosis’
tumours, and the Wound signature to subdivide tumours into
‘activated’ and ‘quiescent’ tumours, subgroups of patients with
markedly different prognosis can be identified. Additional gene
expression signatures are being tested in this series of tumours to
arrive at an optimal prognostic classifier and to obtain improved insight
into breast cancer biology.
In the study to identify predictive profiles, 10 (20%) of the 48 patients
showed (near) pathological complete remission of the primary tumour
after treatment [4]. No gene expression pattern correlating with
response could be identified for all patients, or for the AC or AD
treated groups separately.
Conclusion Various gene expression profiles in breast cancer are
associated with the propensity of the tumour to develop distant
metastases. Gene expression profile predicting the response of primary
breast carcinomas to AC or AD based neoadjuvant chemotherapy are
most likely to be very subtle and cannot be detected when small series
of patients are studied. Genetic tests derived from gene expression
profiling studies are likely to become useful as prognostic and
predictive tests to guide clinical decision making in the treatment of
primary breast cancer.
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Gene expression profiles and molecular classification
to predict distant metastasis and tamoxifen-resistant
breast cancer
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JA Foekens1, Y Wang2
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Introduction Genome-wide measures of gene expression can identify
patterns of gene activity that subclassify tumours and might provide
better means than are currently available for individual risk assessment
in patients with primary breast cancer and for prediction of tamoxifen
resistance.
Methods We analyzed, with Affymetrix Human U133a GeneChips, the
expression of 22,000 transcripts from total RNA of frozen tumour
samples from 286 lymph node negative (LNN) patients who had not
received adjuvant systemic treatment. In a separate second study
conducted in 112 estrogen receptor (ER)-positive primary breast
carcinomas from patients with metastatic disease and clearly defined
types of response to first-line treatment with tamoxifen, a 18,000
human cDNA microarray was used to discover gene expression
profiles predictive of tamoxifen resistance.
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Results In the first single-center study, in a training set of 115 tumors
(80 ER+ and 35 ER– tumors) we identified a 76-gene signature (60
genes for ER+ and 16 for ER–) for predicting the occurrence of distant
metastasis within 5 years. This signature was successfully validated
with 93% sensitivity in an independent test set of 171 LNN patients as
a whole, irrespective of age or ER status. The 76-gene profile was
strongly predictive of those patients who will develop a distant
metastasis within 5 years or will remain recurrence free during that
period (hazard ratio [HR] 5.67; P < 0.00002) and in multivariate
analysis when corrected for traditional prognostic factors including
grade (HR 5.55; P < 0.00003). Analogously, the 76-gene expression
profile strongly predicted overall survival (HR 8.62; P < 0.00002). The
76-gene profile was also a strong prognostic factor in the subgroup of
79 patients with a tumor size ranging from 10 to 20 mm (HR 14.1;
P < 0.00003) and in 84 premenopausal patients (HR 9.60; P < 0.0002)
and 87 postmenopausal patients (HR 4.04; P = 0.0017). In the
subgroup of 42 ER– patients in the validation set, even a profile of only
16 genes appeared to have a strong prognostic value (HR 8.74;
P = 0.012). Recently, our 76-gene expression signature was
successfully validated in a separate multicenter European study of 180
patients from four institutions (Nijmegen, Munich, Bari, Ljubljana) (HR
7.41; P < 0.0001) with similar sensitivity and specificity.
In the second study, conducted in 112 patients with metastatic
disease, using a training set of 46 breast cancers 81 genes were found
to be differentially expressed between tamoxifen-responsive and
-resistant tumors. From the 81 genes, a predictive signature of 44
genes was extracted and validated in an independent set of 66 tumors.
This 44-gene signature is significantly superior (odds ratio [OR] 3.16;
P = 0.03) to traditional predictive factors in univariate analysis and
significantly related to longer progression-free survival in univariate as
well as in multivariate analyses (P = 0.03). The predictive value of the
44-gene signature was recently confirmed in an extended series of 280
patients with advanced disease.
Conclusion In the first study, the identified 76-gene signature provides a
powerful tool for identification of patients at high or low risk for distant
recurrence or death due to breast cancer, allowing clinicians to adapt
choices of adjuvant systemic therapy. In the second study, the 44-gene
signature predicts tamoxifen resistance more accurately than do traditional
predictive factors. Interestingly, in a third study DNA methylation status
also appeared to be useful in predicting tamoxifen resistance.
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Methods for gene expression profiling in clinical
trials for breast cancer
S Paik
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Project, Pittsburgh, Philadelphia, USA
Breast Cancer Research 2005, 7(Suppl 1):S3 (DOI 10.1186/bcr1207)
High throughput gene expression profiling provides a powerful tool for
discovery of prognostic and predictive markers for breast cancer [1-4].
The main limitation to this approach is the requirement for high-quality
RNA, which is difficult in the multicenter clinical trial setting. One
solution is to use RNAlater, which allows procurement and shipping of
tissue specimens at room temperature [5,6]. The National Surgical
Adjuvant Breast and Bowel Project (NSABP) has conducted a pilot
study to procure pretreatement core biopsy specimens in a
neoadjuvant study. Most of the samples in this study provided high-
quality RNA, as determined by Bioanalyzer and Affymetrix GeneChip
analyses. When combined with a RNA amplification method, quality
data could be obtained from 10 ng of total RNA as starting material.
NSABP currently has two neoadjuvant trials in which pretreatment
specimens are procured in RNAlater. However, the typical practice
pattern in the USA makes it difficult to procure tissue in the adjuvant
setting even with the use of RNAlater. Therefore, methods that permit
high throughput gene expression profiling of formalin-fixed, paraffin-
embedded materials are in great need. Such methods will also allow
interrogation of archived tissue banks with annotation established from
previously finished trials and will therefore shorten the time for marker
development and validation. Chemical modification by formalin and
degradation during storage make RNA extracted from paraffin a poor
substrate for gene expression profiling [7]. We have examined both
microarray and RT-PCR platforms for this purpose. In general
microarray analysis using the Arcturus Paradise system has been a
disappointment in our hands, with high rate for assay failure for
materials older than 3 years. However, there are RNA amplification and
labeling methods in development that are not dependent on oligo-dT
priming for cDNA synthesis and may provide better results. In
collaboration with Genomic Health, Inc., we have explored the use of
high-throughput real time RT-PCR for discovery and validation of
prognostic markers for node negative and estrogen receptor positive
breast cancer [8]. This has resulted in development of the OncotypeDx
assay, which is offered as a commercial reference laboratory test. The
disadvantage of real-time RT-PCR assays is relatively low throughput
(less than 1000 genes, even at industrial scale). DASL assay from
Illumina is a kind of hybrid between PCR and microarray platforms, and
may provide relatively cost-efficient means by which to assay many
candidate genes using degraded RNA obtainable from paraffin blocks
[9].
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Gene expression profile-based predictors of
response to chemotherapy
L Pusztai
Anderson Cancer Center, Houston, Texas, USA
Breast Cancer Research 2005, 7(Suppl 1):S4 (DOI 10.1186/bcr1208)
A molecular test that could help in selecting the most effective
chemotherapy for a particular individual could save patients from
unnecessary toxicity, and the right choice of drugs may save lives,
particularly in the adjuvant treatment of breast cancer. Administration of
chemotherapy before surgery provides an attractive opportunity to
discover predictors of response [1]. Pathologic complete eradication of
cancer from the breast and lymph nodes (pCR) represents an extreme
form of chemotherapy sensitivity and invariably heralds excellent long-
term survival. We adopted pCR as an early surrogate of clinically
meaningful benefit from therapy and as an outcome that is worth
predicting. There are simple clinical and histological parameters,
including grade, estrogen receptor status and tumor size, that can be
combined into powerful prediction scores. However, these clinical
variables do not yield treatment regimen specific predictions, and they
cannot be used to select one therapy over another. Assessment of
traditional single gene markers of chemotherapy sensitivity has not yet
resulted in clinically useful tests. Gene expression profiling, which
enables simultaneous measurement of thousands of genes, represents
a promising new tool that may be applied to this clinical problem. It is
currently unknown what the best strategy is to discover response
predictors from high dimensional gene expression data. The simplest
approach may be to search for the single most informative gene that is
differentially expressed between responders and nonresponders. This
may lead to new mechanistic insights into the biology of chemotherapy
response and could yield easy-to-use but moderately powerful single
gene predictive markers [2]. Another approach is to identify gene
expression signatures that are predictive of response, assuming that
the combined information provided by multiple genes would result in
more accurate predictions than any single gene can do. Several small
studies have suggested that this is feasible [3]. Large-scale validation
of these results is needed and is currently underway. Yet another
approach is to recognize the different molecular subtypes of breast
cancer and attempt to develop distinct predictors for each subtype [4].
This approach assumes that, by focusing on the molecularly more
homogenous subgroups, more accurate predictors could be developed
than by analyzing all breast cancers together. We shall present results
from our own research program, illustrating the successes and
limitations of each of these approaches.
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Present situation and future of genetic profiling for
prognosis and treatment
GN Hortobagyi
Department of Breast Medical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, Texas, USA
Breast Cancer Research 2005, 7(Suppl 1):S5 (DOI 10.1186/bcr1209)
Classification and staging systems are important in oncology to predict
clinical behavior and determine prognosis. In addition, they may
contribute to the selection of optimal treatment strategies. Much
clinical and translational research over the past 30 years was directed
at establishing or refining prognostic and predictive factors for breast
cancer. Initially, tumor related factors such as size, grade, lymph node
involvement, and hormone receptor status were considered in the
determination of prognosis. Patient characteristics, such as age,
menopausal status and performance status, also contributed to these
estimates. Some factors such as estrogen receptor (ER) status were
shown to be better predictive factors than prognostic factors. Thus,
although ER-positive tumors have a slightly better prognosis during the
early years of follow up than do ER-negative ones, the major application
of ER status is to predict response to endocrine therapy. A variety of
biochemical and molecular factors were reported to have prognostic or
predictive ability over the past 20 years. These included cathepsin D,
HER2, EGFR, p53, UPA, PAI, and many others. Of these, only HER2
was consistently validated as a prognostic factor, as well as a predictor
of response to the monoclonal antibody trastuzumab (Herceptin).
Developing, assessing, and discarding these various putative
prognostic and/or predictive factors was the result of an enormous
investment of time and effort of many scientists from many countries
around the world. Considering that only one new prognostic/predictive
factor was universally adopted over the past 25 years (HER2 status), it
must be concluded that this is an enormously inefficient process.
The Human Genome Project was a major milestone in the history of
medicine. Both the genetic information obtained and the technological
advances that took place during this large multicenter effort have had
enormous influence over all fields of medicine. For the field of
prognostication and prediction in breast cancer, the major consequence
was the development of technology that led to the simultaneous
evaluation of gene expression for hundreds and, more recently, thousands
of genes. In fact, recently launched gene arrays include the entire human
genome. Thus, we have the opportunity to assess, in a small tumor
sample, the expression profile of all known human genes. There are
multiple technological platforms under evaluation for this purpose, and the
results obtained with one cannot automatically be substituted for results
obtained with another platform. Nevertheless, on the basis of several
reports, it can be stated that gene expression profiling of human breast
cancer provides valuable information in the following areas:
1. Molecular classification of primary breast cancer
2. Identification of multiple distinct prognostic subgroups
3. Determination of expression level of several genes of interest (ER,
PR, HER2, etc.)
4. Identification of genetic networks
5. Prediction of response to chemotherapy
The initial reports were based on small patient numbers that presented
substantial statistical challenges for adequate estimation of end-points
and to prevent frequent false-positive or false-negative results. More
recent analyses have included several dozen and up to a few hundred
patients. These reports provide greater statistical power and greater
reliability. However, these reports still represent retrospective analyses
of subsets of patients, and prospective validation is still sorely needed.
Reports are beginning to appear comparing the performance of
different platforms on the same tumor samples and considering the
same end-points. The source of tumor material, the manner in which it
was handled before testing, and the amount of tissue needed for
reliable testing are all under intense scrutiny. Gene profiling with
currently available platforms includes a number of genes or gene
Available online http://breast-cancer-research.com/supplements/7/S1
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segments of uncertain function (ESTs). These provide an excellent
opportunity to assess the functional value of these genes and enrich
our understanding of their biological function. Many centers and
groups are assessing the potential of molecular profiling in the
prediction of response to therapy. As technology evolves, this type of
information will transform the way we think of breast cancer, the way
we assess and stage primary and metastatic breast cancer, and the
manner in which we select the best combination and sequence of
therapies to obtain optimal therapeutic results. Today’s costs, while
substantial, are rapidly falling and newer technology will make these
assays much more accessible. Furthermore, because multiple relevant
markers can be determined using a single assay, it is likely that gene
expression profiling will be more cost-effective than currently used
diagnostic and prognostic tests.
The major challenges in gene profiling are still in developing and using
the most appropriate statistical methods for data analysis. The need for
handling tens of thousands or hundreds of thousands of data points,
especially originating from a much smaller number of tumors, is
daunting and mistaken conclusions might be reached in the absence of
optimal analytical techniques.
Finally, prospective validation of the clinical utility of gene profiling for
classification, determination of prognosis, and selection of optimal
therapies for individual patients will require large, prospective,
multicenter, controlled clinical trials. If successful, these will take us
one step closer to individualized medicine.
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The role of magnetic resonance imaging as an
imaging tool to assess disease status and residual
disease in locally advanced breast cancer
M Cristofanilli
Department of Breast Medical Oncology, The University of Texas, MD
Anderson Cancer Center, Houston, Texas, USA
Breast Cancer Research 2005, 7(Suppl 1):S6 (DOI 10.1186/bcr1210)
Magnetic resonance imaging (MRI) is a very sensitive diagnostic tool
for the evaluation of breast cancer. A MRI is more frequently utilized in
conjunction with other diagnostic modalities, particularly mammogram,
to better assess a breast abnormality or biopsy-proven cancer,
including ductal carcinoma in situ (DCIS) [1]. Most recently it has also
been demonstrated to be a better screening tool for women at high risk
for developing breast cancer, including women with documented
genetic predisposition. Because MRI has the advantages of providing a
three-dimensional view of the breast, it has been shown to be more
precise than standard imaging in determining the initial staging and
evaluation of the extension of invasive disease [2]. This information is of
particular value in patients with locally advanced disease, including
inflammatory breast cancer (IBC) and in classic lobular histology, which
may exhibit diffuse involvement of the breast at initial presentation and
therefore are frequently treated with primary systemic therapy (PST) [3,4].
The management of primary breast cancer has evolved significantly in
the past decade, with the increasing use of preoperative or primary
chemotherapy (PST), and most recently also primary hormonal therapy
for both early and locally advanced breast cancers (LABCs). The
advantages of the early use of systemic therapy are considered: the
feasibility of a more conservative surgery, and the possibility of true in
vivo testing of the tumor’s drug sensitivity. The amount of residual
disease found following surgical excision represents the pathological
response to the preoperative treatment and remains the most important
prognostic factor.
The high staging accuracy of breast MRI makes it an attractive method
for assessing tumor response to PST. MRI can contribute in several
ways to the management of patients receiving preoperative chemo-
therapy, including the initial determination of extent of disease for
proper staging (baseline evaluation), early identification of poor
responders (intermediate evaluation during treatment), and
identification and description of the presence and extent of residual
disease for surgical planning (preoperative imaging study) [3,4]. MRI
measurements of tumor response may have predictive value for
disease recurrence and responsiveness to novel therapeutics.
Comparison of dynamic parameters (e.g. signal enhancement ratio) at
baseline and at subsequent evaluation time points can also contribute
information on the response to treatment and predict residual disease
[4]. A series of prospective trials has been conducted in patients with
LABC, including IBC. Most recently a large multicenter trial sponsored
jointly by the American College of Radiology Imaging Network, the
Cancer and Leukemia Group B, and the National Cancer institute is
integrating serial MRI tumor measurements with serial collection of
tissue for evaluation of biomarkers (expression, genomic, protein arrays,
as well as specific immunohistochemical markers and fluorescence in
situ hybridization). The goal of such studies is to compare tissue
assessment of biomarkers with imaging to identify the most appropriate
tool for prediction of pathological response to PST. This study could
impact on the present management of primary breast cancer by
allowing the early introduction of novel therapeutics in patients with
early demonstration of poor response to treatment.
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The roles of PET and CT/PET as preoperative studies
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1Instituto PET Focuscan, Madrid, Spain; 2Nuclear Medicine
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Introduction Positron emission tomography (PET) with 18F-fluoro-
deoxyglucose (FDG) is a functional imaging technique that has
demonstrated advantages over anatomically based imaging modalities
Breast Cancer Research    Vol 7 Suppl 1 VI Madrid Breast Cancer Conference
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in oncology in the detection of malignant lesions. The recent
introduction of combined computed tomography (CT)/PET systems
allows the coregistration of functional PET and anatomical CT images,
which will very likely improve accuracy. The role of PET and CT/PET in
breast cancer is reviewed.
Methods In breast cancer, FDG-PET has been used for detection,
staging, and response monitoring; one of its main clinical applications
is defining the extent of recurrent or metastatic disease [1]. We have
reviewed the evidence regarding the roles of PET and CT/PET as
preoperative studies in breast cancer.
Results The review of the evidence shows that PET and CT/PET can
contribute to patient diagnosis and management as preoperative
studies in breast cancer in the following situations:
1. Detection of primary breast cancer. When evaluating suspicious
breast abnormalities, FDG-PET has a sensitivity of 80–100% and
specificity of 75–100%. However, its role in primary tumor
detection is not clear when compared with conventional imaging
methods and remains to be determined [1].
2. Prognostic value of FDG uptake in primary tumor. Most studies
suggest that the level of FDG uptake in primary breast tumors
carries clinical and biological information, and that a higher FDG
uptake is correlated with more clinically aggressive tumors [1].
This information may help to stratify patients according to
prognosis and risk for recurrence, and may help to tailor
treatments to the individual patient.
3. Axillary node staging. In this situation, FDG-PET had a sensitivity
of 57–100% and specificity of 66–100%. FDG-PET under-
estimates the number of tumor-involved nodes compared with
pathologic evaluation from conventional dissection. Therefore,
FDG-PET should not replace axillary node sampling for routine
staging of the axilla because even microscopic nodal involvement
may be important for prognosis and treatment planning [1].
However, FDG-PET may be complementary to sentinel lymph
node mapping and other standard axillary procedures in patients
with more advanced tumors or equivocally palpable axillary nodes.
4. Detection of locoregional and distant metastases. Functional
imaging with FDG-PET is more accurate than CT for the detection
of nodal involvement in the mediastinum; the sensitivity of FDG-
PET was significantly higher (85%) than CT (50%), with nearly
the same specificity (90% for FDG-PET versus 83% for CT).
Regarding the detection of distant metastases, FDG-PET can
accurately detect sites of distant disease with a sensitivity of
80–97% and specificity of 75–94% [1].
5. Evaluation of therapy response. In locally advanced breast cancer
(LABC), the assessment of response to neoadjuvant
chemotherapy with conventional imaging methods is often
inaccurate or slow because it depends on morphological criteria.
Initial studies have shown the utility of FDG-PET in the evaluation
of treatment response, specifically in its ability to discriminate
responders from nonresponders more accurately and earlier than
conventional imaging methods [1]. Changes in FDG uptake after
a single course of chemotherapy can predict pathological
response in primary LABC tumors [2,3]. Histopathological
response could be predicted with an accuracy of 88–91% after
the first and second course of chemotherapy [3]. Other PET
tracers may be used in the evaluation of the primary tumor;
preliminary results suggest that applying PET in this way may help
to identify physiologic manifestations of drug resistance, which
would help to tailor systemic therapy [1]. Preliminary data also
suggest that FDG-PET may be useful in the assessment of sites
of disease other than the primary tumor for monitoring response
to chemotherapy in advanced breast cancer. Initial studies
suggest other possible applications of FDG-PET, such as
evaluation of the response of skeletal metastases to therapy, and
prediction of the response to antiestrogen therapy in patients with
advanced estrogen receptor positive breast cancer [1].
Regarding CT/PET, to date only few studies have been reported,
but the advantages of CT/PET compared with PET alone may be
taken to indicate that CT/PET may improve the accuracy in the
evaluation of treatment response by directly defining metabolic
and morphological changes [4].
6. Future applications. FDG is the most important radiotracer for
PET in breast cancer and therefore it is analyzed in most studies.
However, in the near future more specific PET
radiopharmaceuticals may help to guide treatment, individualizing
therapies to a particular patient depending on the tumor’s biologic
characteristics [1]. PET may help in management decisions by
quantifying the therapeutic target, identifying resistance factors,
and measuring early response to therapy.
Conclusion The clinical application of PET and CT/PET in breast
cancer will help to predict clinical behavior, and allow one to choose
the appropriate treatment and to tailor local treatment options to the
individual patient. PET and CT/PET are also likely to play key roles in
monitoring systemic therapy and evaluating the response to therapy at
an earlier stage than conventional methods. In the future, PET may be
applied with other tracers in addition to FDG, to improve
characterization of tumor biology and more effectively measure
response to therapy.
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Introduction We conducted a study to determine whether a group of
estrogen-induced genes could be used to detect and monitor for
micrometastases in the bone marrow of patients with breast cancer.
Methods We data-mined for potential markers of estrogen action,
verified their relationship to ER in cell lines and purified cells from
patient biopsies, and checked their estrogen-inducibility after
developing a real-time quantitative PCR assay for each. We then
examined 99 bone marrow samples obtained over 2 years during the
follow up of good (n = 7) or poor (n = 19) prognosis patients to
determine the expression frequency.
Results We discovered that the expression of eight out of 23 genes,
identified by data-mining, were estrogen-regulated. We developed real-
time quantitative PCR (QPCR) assays for measurement of the genes
for which ESTs were available (ER-α, PR and GATA-3, EEIG-1, EP-3,
PS2). We examined their expression in purified breast cancer cells
from primary cancers and also from metastases from endocrine-
resistant cancers and confirmed that these genes were still expressed.
Of these, three were expressed in peripheral blood, excluding them as
candidate markers. We then examined 79 samples of bone marrow
from 19 poor prognosis patients and 20 from seven good prognosis
patients. We found that GATA-3 and ER expressions were significantly
higher in the bone marrow of poor-prognosis patients.
Conclusion GATA-3 and ER appear to be potentially useful markers, in
addition to CK19, for monitoring the effects of treatment in the bone
marrow of patients with ER-positive breast cancer.
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The detection of microscopic disease in breast cancer has been
evaluated in lymph nodes, bone marrow (primary breast cancer), and
peripheral blood (metastatic disease) [1,2]. Most of these studies
demonstrated that the detection of microscopic disease in breast
cancer patients contributes prognostic information and, in selected
cases, can predict the efficacy of treatments [1,2]. In primary breast
cancer, the detection of microscopic disease in lymph nodes and bone
marrow has led to a better understanding of the role of minimal residual
disease (MRD). In metastatic breast cancer (MBC) reliable detection of
circulating tumor cells (CTCs) had been obtained by using immuno-
magnetic separation and subsequent analysis by the CellSpotter™
analyzer (Veridex LLC, a Johnson & Johnson company, Warren, NJ,
USA). This technology is becoming a standard tool for the ‘real-time’
assessment of prognosis and response to treatment. This is particularly
important in the context of advanced disease management, considering
the incurable status of the disease and the increasing therapeutic
options available that could at least contribute to improve palliation and
impact on overall survival.
In fact, despite years of clinical research, the odds of achieving
complete response, and hence major survival benefit, for patients with
MBC remain extremely low. Only a few patients who achieve a
complete response after chemotherapy remain in this state for
prolonged periods of time, with some remaining in remission beyond
20 years. There are presently no reliable biological markers that can
predict prognosis and monitor therapy effects in MBC.
The detection of CTCs in patients with MBC about to start a new line
of treatment has been shown to predict progression-free survival (PFS)
and overall survival (OS). This prognostic value was independent of the
line of therapy (e.g. first-line versus second-line or more) [2,3].
Moreover, in multivariate analysis CTCs demonstrated superior value
compared with site of metastasis (e.g. visceral versus soft tissue/bone),
type of therapy, and length of time to recurrence after definitive primary
surgery. In recent analysis, detection of CTCs has also been found to
be prognostic in patients with bone-only disease (not measurable
disease). CTCs have been shown to be superior to standard tumor
markers (e.g. Ca27-29) in predicting prognosis. Furthermore, the
efficacy or benefit to systemic therapy could be predicted by the level
of CTCs as early as 3-4 weeks after initiation of therapy. Patients with
persistent of ≥5 CTCs demonstrated lack of response or progressive
disease at the time of restaging by standard imaging modalities.
Conversely, patients with < 5CTCs showed objective remission. These
data clearly suggest that CTCs can be used as an early predictor of
treatment efficacy and be extremely useful in sparing patients from
futile therapy early in the course of their treatment.
Prospective clinical trials are presently being conducted in MBC to
validate further the prognostic value of CTCs, possibly to use this
diagnostic tool to better stratify patients with metastatic disease,
eventually modifying the current staging system (International Stage IV
Stratification Study [ISSS]). Patients with metastatic disease could be
divided into the subcategories IVA and IVB, depending on the presence
or absence of CTCs. Additional studies are presently assessing the
survival benefit of early change in treatment based on the persistence
of CTCs and the possibility of collecting the cells, after sorting for
evaluation of biomarkers (RT-PCR, gene profiling). Exploratory studies
in PBC are also being conducted.
This technology could be integrated with other new investigation tools
to develop blood-based integrated platforms that will facilitate
screening, diagnosis, prognosis and target discovery. A recent
acquisition is represented by the use of glycan arrays [4].
Malignant transformation and tumor progression are associated with
the specific changes in the complex surface carbohydrates known as
tumor-associated carbohydrate antigens (TACAs). Production of
autoantibodies against these abnormal carbohydrates during cancer
progression is expected. A robust printed glycan array was recently
fabricated that employs a library of over 200 well defined structures
comprising carbohydrate sequences of N-glycans, O-glycans,
glycolipids, and glycoproteins. This printed glycan array was used to
simultaneously detect multiple specific antiglycan autoantibodies in
sera from breast cancer patients.
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Breast reconstruction following radical mastectomy, if desired, is
considered vital to the patient’s rehabilitation and is an intrinsic part of
her breast cancer treatment. Immediate reconstruction – especially
immediate reconstruction using autologous tissues – has become
more established since the introduction of the skin-sparing mastectomy
in the early 1990s. Now, as the more current therapeutic armamen-
tarium has been expanded to feature preoperative tumor shrinking with
chemotherapy, accelerated or partial breast radiotherapy, and, in
particular, the increased use of breast conservation surgery for larger
tumors, immediate breast reconstruction techniques have also further
evolved to address the radical mastectomy defect with newer micro-
surgical techniques and autologous flap tissues, such as the IGAP,
gracilis [1], and SIEA flaps, as well as improved silicone and anatomic
saline implant designs [2] with post-operative adjustment capabilities
designed to facilitate longer term symmetrical breast reconstruction
outcomes.
The increased use of postmastectomy radiation therapy in patients with
early-stage breast cancer has increased the complexity of planning for
immediate breast reconstruction. Studies have evaluated the outcomes
of breast reconstruction performed before radiation therapy, revealing a
high incidence of complications and poor aesthetic outcomes [3].
Moreover, immediate breast reconstruction can interfere with the
delivery of postmastectomy radiation therapy. Multidisciplinary breast
conference identification of early breast cancer patients at high risk for
radiation therapy has evolved a unique and highly successful ‘delayed
immediate’ reconstruction [4] approach that preserves the aesthetic
outcomes of immediate reconstruction and avoids radiation injury to the
reconstructive tissues. This is accomplished by utilizing a filled
subpectoral tissue expander to temporarily preserve the breast skin
envelope until the final tissue pathology is confirmed and the patient
either goes on to definitive reconstruction or to radiation therapy with
the expander deflated. A total of 28 high-risk early breast cancer
patients have undergone the delayed immediate approach with 20
patients (71%) not ultimately requiring radiation therapy. Nineteen
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patients in the non-radiated group (95%) have now completed
definitive reconstruction, primarily with the use of autologous tissues.
The eight patients who required radiation have completed the radiation
therapy and six (75%) have undergone tissue re-expansion and skin-
preserving delayed reconstruction designed to be as similar in
outcome to immediate reconstruction as possible. The complication
rate for the initial expander placement at the time of mastectomy was
18% for all patients. Five nonradiated patients (25%) had
complications in the second stage of definitive reconstruction and one
patient (17%) following radiation therapy had complications in the skin-
preserving delayed reconstruction.
Finally, following the successful experience of the delayed immediate
approach for early breast cancer patients, 17 advanced stage patients
with planned postoperative radiation therapy also had the opportunity
for skin-preserving tissue expansion prior to radiation therapy upon
multidisciplinary approval. All the patients received neoadjuvant
chemotherapy. Five of the patients (29%) had complications in the first
stage of expander placement but two patients (12%) have now
completed definitive reconstruction following radiation therapy with re-
expansion of preserved breast skin and have experienced no
complications.
Immediate reconstruction minimizes incisional scars on the breast and
improves overall breast contour, shape, and appearance. The improved
aesthetic outcomes over delayed reconstruction, achieved as well by
these diverse skin-preserving ‘delayed immediate’ approaches without
significant incidents of complications, has convinced many breast
cancer patients to view mastectomy with reconstruction as a viable and
positive treatment choice.
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Introduction Lymphatic mapping and biopsy of the sentinel lymph
nodes (SLNs) as a method for pathologically staging breast cancer
patients has been extensively evaluated over the past 10 years. The
goal of this approach is to stage patients accurately in order to make
appropriate decisions about adjuvant treatment, but also to avoid the
potential morbidity of conventional axillary lymph node dissection
(ALND). A large number of single center and multicenter trials have
been reported that indicate the accuracy of several different methods,
and the largest prospective randomized trial of SLN biopsy versus
ALND, conducted by the National Surgical Adjuvant Breast and Bowel
Project (NSABP), completed accrual last year. Other trials with
different designs and objectives have also been completed. A great
deal of information is now available on the use of this approach to
breast cancer staging, but many questions remain controversial,
including technical issues and patient selection parameters.
Methods A review of the literature was performed, with particular
attention to recently reported results from the NSABP’s B-32 trial and
the UK ALMANAC trial.
Results Single center and multicenter validation trials of sentinel node
biopsy for breast cancer have demonstrated success rates varying
from under 70% to 100%, accuracy rates from 95% to 100%, and
false-negative (FN) rates from 0% to 19% [1]. The NSABP B-32 study
is a randomized trial comparing SLN biopsy alone versus SLN biopsy
plus ALND. Patients with positive SLN by routine histology (without
immunohistochemical staining) underwent completion axillary node
dissection. A total of 5611 patients were accrued to this trial, and the
technical results and accuracy of SLN biopsy were recently reported
[2]. At least one SLN was identified in over 97% of the evaluable
subjects, and the SLN was positive for metastases in 26%. The FN rate
in the group who also had an ALND was 9.7%. The SLN was the only
positive node in 61.5% of patients, and only 0.6% of patients had a
positive SLN outside of the axilla. SLN identification improved with
increasing surgeon experience, and the FN rate was higher after
surgical biopsy of the breast versus needle biopsy. In the ALMANAC
trial, patients were randomly assigned to SLN biopsy or ALND.
Analysis of morbidity demonstrated markedly decreased functional
sequelae after SLN biopsy versus ALND, especially in the incidence of
sensory loss and arm edema [3].
Issues that are controversial include technical parameters, such as the
use of a radionuclide or visible dye alone versus the combination, the
sites of injection (subareolar, intradermal, or intraparenchymal), and
timing of injection. Several patient selection factors, such as age,
obesity, tumor size, and multicentricity, may also impact on the success
rate and accuracy of SLN biopsy. Some have advocated routine use of
SLN biopsy in patients with ductal carcinoma in situ (DCIS), but it is
not clear that this impacts on treatment decisions. It is appropriate to
consider SLN biopsy in patients with extensive DCIS diagnosed by
needle biopsy, especially if there is a high risk for finding invasive
cancer on definitive excision or if the patient is undergoing a total
mastectomy. The prognostic significance of ‘occult’ micrometastases
found in SLN by immunohistochemistry is uncertain, but will hopefully
be resolved by the NSABP B-32 trial and the American College of
Surgeons Oncology Group (ACOSOG) Z0010 study. There is also
great interest in being able to predict accurately which patients with a
positive SLN have no other nodes involved and could therefore avoid
completion ALND. Finally, there is disagreement about the role and
timing of SLN biopsy in breast cancer patients receiving neoadjuvant
chemotherapy. The FN rates for SLN after chemotherapy have been
extremely varied, but in the largest series of patients who underwent
SLN biopsy and ALND after chemotherapy (in the NSABP B-27 trial)
the FN rate was 10.7% and was not affected by clinical nodal status
prior to treatment [4].
Conclusion SLN biopsy, in experienced hands, is a very accurate
method for assessing lymph node status in women with breast cancer
and clinically negative nodes. A surprising array of techniques and
patients selected for the procedure appear to be successful. SLN
biopsy has the potential to reduce drastically the incidence of morbidity
related to surgical staging of the regional lymph nodes in women with
breast cancer.
References
1. Kelley MC, Hansen N, McMasters KM: Lymphatic mapping and
sentinel lymphadenectomy for breast cancer. Am J Surg 2004,
188:49-61.
2. Julian TB, Krag D, Brown A, et al.: Preliminary technical results
of NSABP B-32, a randomized phase III clinical trial to
compare sentinel node resection to conventional axillary dis-
section in clinically node-negative breast cancer patients
[abstract]. Breast Cancer Res Treat 2004, 88:S11-S12.
3. Mansel RE, Goyal A, Fallowfield L, Newcombe RG: Sentinel
node biopsy versus standard axillary treatment: results of the
randomized multicenter UK ALMANAC trial [abstract]. Breast
Cancer Res Treat 2004, 88:S13.
4. Mamounas EP: Sentinel lymph node biopsy after neoadjuvant
systemic therapy. Surg Clin North Am 2003, 83:931-942.
Available online http://breast-cancer-research.com/supplements/7/S1
S8
S12
Partial breast irradiation: why and how
FA Calvo1, JA Díaz2, Á Montero3, A Álvarez González1
1Hospital General Universitario Gregorio Marañón, Madrid, Spain;
2Clínica Universitaria de Navarra, Madrid, Spain; 3Hospital Ramón y
Cajal, Madrid, Spain
Breast Cancer Research 2005, 7(Suppl 1):S12 (DOI 10.1186/bcr1216)
Introduction Successful treatment of early breast cancer, with high
cure rates and excellent cosmetic results, is a reality that has been
achieved in the past 25 years due in part to the use of post-
tumorectomy whole breast radiotherapy [1]. The EORTC randomized
trial questioned the need for radiation boost to the post-tumorectomy
surgical bed, with an evident age-related local control effect [2].
Furthermore, examination of the topography of breast cancer
recurrences after breast conservation, whether or not a radiotherapy
treatment component was included, revealed that recurrences
developed in the operative area in 90% of cases [1]. These factors
have stimulated emerging interest in exploring partial breast irradiation
(PBI) in early breast cancer. Intraoperative radiation therapy (IORT) is
an appropriate technical alternative to delivering PBI, together with high
dose rate brachytherapy and/or external irradiation precision
techniques (3DCRT, IMRT).
Method IORT implies delivery of a high, single dose of radiation to a
limited intrasurgical anatomic area. In the case of post-tumorectomy
early breast cancer, the target volume is the tumor bed, maintaining a
safety margin in depth (thickness of tissue to be treated) and laterally.
Dosimetrically, electrons and high dose rate brachytherapy are well
suited to these requirements. Intrabeam (soft X-rays at 50 kV),
mammosite 3DCRT and IMRT are alternative technologies that have
been adopted into clinical radiotherapy practice and have theoretically
favourable dose–gradient effects. Target size, normal tissues included
in the radiation fields, and operative/treatment time are variables that
differ for each individual patient. The optimal PBI dose is under
investigation based upon radiobiological dose-effects models. An
efficient therapeutic index in IORT trials has been identified, with boost
doses in the range 10–12.5 Gy (maximum 15 Gy). For IORT single
radiation component, clinical information is scarce [3,4].
Clínical trials Limited institutional experience and pilot studies are
available in the literature describing results with IORT as a boost,
hypofractionated HDRB, or external irradiation. There are two ongoing
randomized trials that have been recruiting patients since 2000 using
Intrabeam system (active in UK, Europe, USA and Australia) and
Novac-7 (electrons; Milan). Both trials are exploring single doses
around 20 Gy. In 2005 a multi-institutional randomized trial including
PBI HDR brachytherapy was initiated. Selection criteria for inclusion
are strict in these trials, and a highly selected group of breast cancer
patients with good prognosis are apparently being investigated. An
extensive review of clinical research considerations, radiobiological
implications, pathology and surgical methodological requirements,
physics specifications, and summary of the available literature was
recently published after a group expert meeting to define the state of
the art and science of PBI, including all available techniques [5].
Discussion Recent randomized trials have questioned the need for
systematic use of whole breast irradiation after lumpectomy in the
context of selection by age, tumor size, or tamoxifen treatment [6].
While the data in PBI consolidate and mature, there is solid evidence
to support moderation in clinical practice modification. Professor
Bartelink [7] has summarized arguments to question the potential
contribution of PBI, in particular IORT, to change clínical practice in the
treatment of early breast cancer. The most relevant issues to be
addressed, for an sceptical or conservative opinion regarding PBI, are
as follows:
1. The omission of external beam irradiation without validated tools
for selection of patients according to biological risk might
compromise local control and survival.
2. The biological effects (both in tumor control and normal tissue
toxicity) of a high single radiation dose, as is used in IORT, or
altered fractionation as is used in other PBI techniques trials are
speculative, with a significant risk for unpredictable late damage
to normal tissue.
3. Target volume definition and dosimetric characteristics of the two
ongoing randomized clinical trials have major methodological and
technical differences, which will make local results uncomparable.
Some additional topics will be introduced for discussion in the
presentation, such as influence of PBI in the radiotherapy management
of metastatic axia, modification of scales for cosmetic assessment,
treatment planning availability, dosimetric disturbances with the use of
shielding material, and opportunities for prospective testing of
biological predictive factors on tolerance of normal tissues.
The mentioned arguments seem valid and should be influential in the
scientific development of PBI for breast cancer. Experts in PBI and
precision radiotherapy for human cancer have been particularly
meticulous in analyzing local effects and topography of recurrences. If
PBI successfully contributes to the treatment of breast cancer, then
surgeons and radiation oncologists should be open minded and
change their clinical practice. Health authorities should facilitate the
appropriate technology to ensure that this particular population breast
cancer patients receives quality treatment.
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The timing of breast reconstruction following mastectomy has been an
area of controversy. Simultaneous or immediate breast reconstruction
(IBR) allows the patient to adjust to the loss of a breast by restoring her
body image. It also reduces the surgical stages involved and provides
an enhanced aesthetic outcome when combined with skin sparing
mastectomy techniques. Still, IBR has not been widely accepted due to
concerns about interference with locoregional recurrence control,
possible delay in adjuvant chemotherapy application and technical
difficulties in postmastectomy radiation therapy delivery.
During this presentation a clinical case discussion will serve as the
introduction to a thorough literature review regarding the oncological
safety and convenience of IBR both for partial mastectomy defects
after breast conservation surgery as well as for skin sparing
mastectomies. Special attention will be given to the main factors
involved in the decision making process, including type, stage, and
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location of the tumour, the necessity for adjuvant therapy, and the
techniques used for breast reconstruction.
All cases should be individually discussed in a multidisciplinary breast
team including pathologists, radiologists, oncologic breast surgeons,
reconstructive plastic surgeons, and medical and radiation oncologists,
with active participation of the patient.
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Introduction Breast-conserving treatment (BCT) constitutes the
predominant approach to local treatment in early stage invasive breast
cancer. This modality of treatment includes breast-conserving surgery
(BCS), radiotherapy, and systemic treatment. These three pillars of
BCT have been intensively studied during the past few decades to
determine their role and possible variations in their application.
Method This panel discusses the state of the art and the current
developments in radiotherapy for patients with early stage invasive
breast cancer treated with BCT. Different radiotherapy options are
systematically presented according to particular clinical scenarios and
available scientific data.
Results Whole breast irradiation (WBI) represents the radiation ‘gold
standard’ after BCS in breast cancer stages I–II. Several randomized
trials, enrolling thousands of patients and with long-term follow up,
have shown a clear improvement in local control when WBI is used
after BCS. A recent meta-analysis has confirmed a threefold increase
in local control rates. In addition, an 8.6% decrease in the risk for death
was demonstrated [1].
Adjuvant chemotherapy and hormone therapy also contribute to
increase local control rates in this group of patients [2]. Substantial
efforts have been made to identify a low-risk subgroup of patients who
do not benefit from radiotherapy after BCS. However, this subgroup
has not been yet identified because even low-risk patients (T <2 cm,
margin negative, EIC negative, age >70 years) do benefit from adjuvant
WBI [3]. Nevertheless, several well known clinical and pathological
factors define a profile of lower risk for local relapse in which more
conservative radiotherapy modalities are being explored.
In this context accelerated partial breast irradiation (APBI) appears to
be a promising alternative to WBI in selected patients, with possible
similar efficacy, a considerable reduction in the treatment length with a
resultant improved quality of life, and potential decreased toxicity.
Different APBI techniques can be used, such as intraoperative
electrons, catheter-based interstitial brachytherapy, MammoSite
Balloon brachytherapy, or external-beam partial irradiation. Encouraging
results with adequate recruitment and medium term follow up have
been published in terms of local control and tolerability, the majority of
them with the use of catheter-based interstitial brachytherapy [4].
However, some concerns remain, particularly regarding potential late
adverse effects and potential differences among techniques. Patient
selection, expertise, and high quality technology and assurance are key
elements to the success of this emerging approach. Current
multicentric randomized trials are ongoing and hopefully will help to
define the ideal criteria for patient selection, the most satisfactory
treatment modality, and the exact role of APBI in terms of outcome and
toxicity.
Conclusion Although WBI remains the radiation standard of care in
early-stage invasive breast cancer after BCS, APBI emerges as
promising approach for treating selected patients.
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Four trials have now reported on the use of tamoxifen for the prevention
of breast cancer and one trial on the use of raloxifene. Overall, more
than 28,000 women have participated in tamoxifen prevention trials
and more than 140,000 women-years of follow up have accrued.
Although early reports on the ability of tamoxifen to prevent breast
cancer were apparently contradictory, with further follow up a
consensus is now emerging indicating that 30–40% of breast cancers
can be prevented by tamoxifen [1]. The benefit is restricted to
oestrogen receptor positive tumours, where it is about 50%, but no
reduction in receptor negative tumours has been found. Thrombo-
embolic events are emerging as the most important side effects, and
endometrial cancers are increased about twofold, although these are
almost all low/intermediate grade, stage I cancers.
Raloxifene does not have the gynaecologic problems of tamoxifen, but
still leads to an increase in thromboembolic events. Recent data from
CORE/MORE [2] suggests that this selective oestrogen receptor
modulator (SERM) may be more effective in prevention than tamoxifen.
Six adjuvant trials have reported on the use of aromatase inhibitors for
early breast cancer. All of them show a marked reduction in
contralateral tumours compared with tamoxifen [3]. The drugs are also
better tolerated and have fewer side effects than tamoxifen, suggesting
that they are very promising agents for breast cancer prevention. These
data will be reviewed and ongoing chemoprevention trials discussed.
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The development of presurgical endocrine strategies for the treatment
of primary breast cancer was developed initially from the application of
such treatments in elderly patients to try to avoid the potential
complications of surgery. Although there are few data available, one
study has indicated that in oestrogen receptor (ER)-positive tumours
clinical responses are as frequent with endocrine therapy as with
cytotoxic chemotherapy. The optimal duration of treatment is not
established, although most trials range between 3 and 4 months. A
randomized trial indicated that the aromatase inhibitor letrozole was
significantly better than tamoxifen when given as neoadjuvant therapy
to patients ineligible for breast conserving surgery (BCS). A similar
result was obtained for anastrozole in another randomized trial
(IMPACT) but no greater efficacy than tamoxifen was seen in tumours
in which BCS was possible. These two studies have provided an
indication that aromatase inhibitors may be significantly more effective
than tamoxifen in HER2-positive tumours. In the IMPACT trial the
changes in the proliferation marker Ki67 were predictive of outcome in
the large ATAC adjuvant trial, supporting the concept of using the
neoadjuvant scenario to assess new therapeutic agents/ideas prior to
initiating large phase 3 studies. The relatively easy availability of tissue
samples during before and during neoadjuvant trials makes this a
particularly valuable arena for translational research studies with new
targeted agents in combination with hormonal treatment.
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the NSABP experience
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Introduction Primary or neoadjuvant systemic chemotherapy, initially
described for patients with locally advanced or borderline inoperable
breast cancer, has been increasingly utilized for patients with less
advanced or operable breast cancer. Theoretically, primary systemic
therapy could inhibit the rapid growth of metastases after surgery and
may decrease the emergence of chemoresistant clones of cells. On a
practical level, primary systemic therapy has the potential to increase
the use of breast conservation by decreasing tumor size. Beginning in
1988, the National Surgical Adjuvant Breast and Bowel Project
(NSABP) cooperative group conducted two sequential trials to test the
value of neoadjuvant chemotherapy and to optimize the treatment
regimen for operable breast cancers.
Methods NSABP Protocol B-18 was designed to compare pre-
operative chemotherapy with doxorubicin (adriamycin) and cyclophos-
phamide (AC) given every 3 weeks for four cycles versus the same
chemotherapy treatment given in the adjuvant setting. In protocol B-18,
1523 women with operable breast cancer were randomized to receive
four cycles of AC followed by surgery or surgery followed by four
cycles of AC. Women 50 years of age or older also received tamoxifen
for 5 years, starting after chemotherapy.
Subsequently, NSABP Protocol B-27 was conducted with the intent to
determine the effect of adding docetaxel (taxotere [T]) after four cycles
of preoperative AC on disease-free survival (DFS) and overall survival
(OS) of women with operable breast cancer. A total of 2411 women
with operable primary breast cancer were randomized to receive either
four cycles of preoperative AC followed by surgery (group I) or four
cycles of AC followed by four cycles of T, followed by surgery (group
II), or four cycles of AC followed by surgery and then four cycles of T
(group III). Tamoxifen was given to all patients, starting concurrently
with chemotherapy.
Results In protocol B-18, mean tumor size was 3.5 cm. Preoperative
AC produced objective clinical responses in 79% of the treated patients
and clinical complete responses (cCR) in 36%. Pathologic complete
responses (pCR, defined as no invasive cancer in the breast) were
observed in 13%. OS and DFS were similar in the two randomized
treatment groups. Preoperative chemotherapy resulted in a statistically
significant increase in the rate of breast conserving therapy (BCT), from
60% to 68%. This was particularly notable in the patients with tumors
>5 cm, in whom BCT was increased from 8% to 22% [1]. Although
there was a trend toward increased ipsilateral breast tumor recurrence
(IBTR) in preoperative chemotherapy patients who were downstaged to
lumpectomy compared with patients treated preoperatively who were
considered to be candidates for BCT at the outset (15.9% versus
9.9%), this difference was not statistically significant after controlling for
patient age and tumor size [2]. Patients in the preoperative
chemotherapy group who experienced a pCR had significantly improved
DFS and OS compared with all other patients in the preoperative
chemotherapy group (P < 0.0001). Clinical response was also
associated with improved outcomes with long-term follow up [2,3].
For protocol B-27, mean tumor size was 4.5 cm; this and other key
characteristics were evenly balanced among the three treatment arms.
The addition of docetaxel preoperatively resulted in significant
increases in cCR and pCR at the time of surgery compared with AC
alone (63.6% versus 40.1% and 26.1% versus 13.7%, respectively)
[4]. Despite this, addition of docetaxel to AC did not significantly
impact on survival in this cohort of patients [5]. There was a trend
toward improved DFS in group II patients who received preoperative T,
but this was not statistically significant (72% versus 67% DFS at
5 years; HR = 0.86, P = 0.10). In an analysis of relapse-free survival
(RFS), which did not include second primary cancers, group II had a
significantly better outcome compared with group I (74% versus 69%
RFS at 5 years; HR = 0.81, P = 0.03). Group III RFS was not
significantly different from group I (71% at 5 years; HR = 0.91,
P = 0.32). Addition of docetaxel significantly reduced the incidence of
local recurrences as first events, including IBTR in patients treated with
breast conservation. There were no significant interactions between
treatment and estrogen receptor status, age, tumor size, or clinical
nodal status. An exploratory analysis of treatment effects in subsets of
patients according to clinical response to AC suggests that preoperative
T, but not postoperative T, significantly increased DFS in patients who
had a partial clinical response after four cycles of AC (63%, 74%, 65%
at 5 years for groups I, II, and III; HR = 0.68 for group II versus group I,
P = 0.003). Addition of T did not appear to be beneficial in patients who
were nonresponders after AC nor in those patients who had a cCR after
AC. Pathologic complete response was a highly significant predictor of
DFS and OS in all treatment groups (HR = 0.45, P < 0.0001, and
HR = 0.33, P < 0.0001, respectively). In addition, pathologic nodal
status after chemotherapy was a significant prognostic factor for survival,
independent of pathologic response in the breast.
Conclusion The B-18 trial did not demonstrate superiority of
neoadjuvant over adjuvant chemotherapy for operable breast cancer,
but with equivalent survival and increased BCT, the neoadjuvant
approach can safely be used to offer BCT to more women with breast
cancer. This trial also demonstrated a strong association between pCR
and improved patient outcomes. In B-27, however, despite a doubling
of the pathologic complete response rate in the breast with the
addition of T preoperatively, we have not yet observed a significant
improvement in DFS or OS for the study as a whole. Addition of
preoperative or postoperative docetaxel decreased the incidence of
local recurrences. There was a decrease in relapses with the addition
of preoperative T, particularly in a subset of patients who had partial
clinical responses to AC alone. Post-treatment pathologic response in
the breast and nodal status remained powerful predictors of patient
outcomes. Future studies will examine the value of additional drugs
given with doctaxel after AC preoperatively and will also be designed to
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assess the ability of genomic and molecular profiles of pretreatment
tumor to predict responsiveness to chemotherapy.
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Adjuvant chemotherapy has traditionally been administered in the
postoperative setting. However, numerous studies have evaluated its
use preoperatively. The potential benefits of neoadjuvant chemotherapy
(NACT) include downstaging the primary tumor to allow breast-
conserving surgery and assessment of a tumor’s in vivo sensitivity to
individual chemotherapeutic regimens. Our group at the MD Anderson
Cancer Center initiated clinical trials with neoadjuvant chemotherapy in
1974, and over the past three decades we have treated several
thousand patients in prospective clinical trials. Initially, NACT was
reserved for the treatment of patients with locally advanced and/or
inflammatory breast cancers. These studies clearly demonstrated that
most patients had a marked reduction in tumor volume with
anthracycline–cyclophosphamide–fluorouracil based regimens.
Inoperable tumors became operable for most patients, and later
studies indicated that even large tumors became candidates for breast-
conserving therapies. We described 20 years ago the prognostic value
of pathological complete remission (pCR), and subsequent studies
included pCR as a surrogate end-point for long-term efficacy. These
findings were later confirmed by the largest study evaluating the impact
of neoadjuvant chemotherapy, the NSABP B-18. In this study, 1523
women were randomized to receive four cycles of doxorubicin and
cyclophosphamide either prior to or after surgical resection. Another
large study of similar design was performed by the EORTC, with similar
results. The timing of chemotherapy did not affect the disease-free or
overall survival for the entire cohort, although more patients who
received preoperative therapy were able to undergo breast
conservation rather than mastectomy in comparison to those treated
postoperatively. These studies confirmed the clear correlation of
pathological complete response (pCR) in the breast (absence of
invasive cancer cells) with survival. Using a single, anthracycline-
containing chemotherapy regimen, a pCR rate of about 10–13% can
be obtained. The definition of pCR used by our group includes the
absence of lymph node involvement, in contrast to the definitions used
by NSABP and other groups. The pCR rate has become one of the
most important intermediate trial endpoints in assessing the efficacy of
new adjuvant chemotherapy regimens. 
Published studies of anthracycline-based preoperative chemotherapy
demonstrate pCR rates of up to 17%. Several recently reported
studies including the sequential use of anthracycline-based regimens
and taxanes have achieved significantly higher pathologic responses,
ranging from 25% to 34%. Our studies focused on the sequential use
of anthracyclines and taxanes, showing excellent tolerance and efficacy
of this strategy. In addition, we demonstrated the therapeutic
superiority of weekly paclitaxel in this setting. These findings were
subsequently confirmed by much larger, randomized trials conducted
by another cooperative group. We used the neoadjuvant strategy for
the initial evaluation of trastuzumab in patients with primary breast
cancer. That small randomized trial indicated an almost threefold
increase in pCR with the addition of trastuzumab to chemotherapy.
Currently, we conduct studies with gene profiling in the neoadjuvant
setting to determine predictors of pCR, and therefore long-term
prognosis, and to develop individualized medicine for patients with
primary breast cancer.
There are multiple remaining questions related to the use of this
strategy, however. Some pertain to optimal local–regional therapies:
when should axillary assessment be performed in relation to NACT,
what should be the criteria for administration of postmastectomy
radiation therapy following NACT, and how to optimally perform breast-
conserving surgery following NACT. The role and relative timing of
neoadjuvant hormone therapy (NAHT) is also under intensive
evaluation at this time. This is solely relevant to the group of patients
with hormone receptor-positive tumors, but has potential impact on the
type and sequence of local, regional and systemic therapies.
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The Oxford Overview of adjuvant endocrine trials [1] indicates that 5
years of adjuvant tamoxifen reduces recurrence by 41% and deaths by
34% in women with oestrogen receptor (ER)-positive breast cancers.
At 5 years, in all patients studied, the recurrence rate was 25.8% in
controls but 13.9% on tamoxifen. There was a substantial ‘carry over’
effect of tamoxifen such that even after 15 years of follow up mortality
was about 30% less in tamoxifen-treated patients. The effect of
tamoxifen was greater in patients with ER-positive, PR-positive as
compared with ER-positive PR-negative tumours. These data indicate a
substantial effect of tamoxifen but it is clear that approximately half of
patients are resistant to tamoxifen de novo (early relapses) or acquire
resistance if we assume that women who relapsed later had an initial
response to tamoxifen. The potential reasons for resistance include
activated growth factor pathways overriding the inhibitory effects of the
drug either via nuclear or membrane ER. Of ER-positive PR-negative
tumours, 30% are HER1/2-positive, as compared with about 10% of
ER-positive PR-positive tumours, and this difference may account for
their lower activity of tamoxifen in PR-negative tumours. Modern
aromatase inhibitors (AIs) are more effective in reducing relapse
compared with tamoxifen whether AI treatment is initiated after surgery
(ATAC and BIG1-98 trials) or after 2–3 years of tamoxifen (ITA,
ARNO/ABCSG). At present, it is difficult to distinguish any differences
in effectiveness between the three agents used in these trials
(anastrozole, letrozole and exemestane) but small differences in toxicity
patterns are beginning to emerge. The reason for the greater
effectiveness of AIs is not clear. In randomized studies of neoadjuvant
endocrine therapy [2] and in the anastrozole adjuvant trials (ATAC and
ARNO/ABCSG) [3], the AIs used were particularly more active than
tamoxifen in the ER-positive PR-negative subgroup of tumours, but this
was not seen in the BIG1-98 and IES trials. Studies on letrozole
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resistant human mammary tumour cell lines show that growth factor
pathways such as MAPK (mitogen-activated protein kinase) are
activated, and sensitivity to the AI can be restored by growth factor
pathway inhibitors [4]. Also, AI resistance can be reduced by combined
treatment with fulvestrant in animal models. These data suggest
mechanisms whereby AI resistance may be circumvented in patients
and point to new approaches to adjuvant treatment.
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The decision about whether to receive systemic adjuvant therapy for
cancer depends on weighing the benefit (in terms of increased relapse-
free or overall survival) against the cost and risk with such therapy. As
the use of adjuvant therapy has been extended into node-negative
breast cancer, the decisions have become less obvious because the
benefit is smaller, particularly as compared with the risks associated
with the therapy and nonbreast cancer mortality. Guidelines can be
helpful in these situations, but a limitation of guidelines is that they
usually are compendiums of expert opinion and provide little
quantitative guidance. In addition, it can be difficult to state guidelines
that can be patient specific when multiple parameters might be used in
the decision (e.g. age, comorbidity state, actual number of nodes,
tumor size, hormone receptor status, histologic grade, and additional
pathologic laboratory evidence).
To address this problem the decision tool Adjuvant! (Fig. 1) was
created [1,2]. It uses data from national databases and other sources
to make estimates of a patient’s baseline prognoses. It uses data from
the Overview, and individual clinical trials to make estimates of
treatment efficacy. It uses national data about age-specific competing
mortality to make estimates of competing mortality. Although the
program provides these estimates, it has the flexibility to allow the user
to modify the estimates as they think appropriate. Over 200 pages of
help files allow the user to review the data on which the program is
based, and the methods used by the program and the assumptions
which it makes. That for the most part these estimates are reasonable
is supported by a validation of Adjuvant!’s estimates in a large
independent database [3]. Specific sheets describing the toxicity and
safety issues of different adjuvant treatment options are included.
The presentation will discuss the strengths and limitations of this
approach. The major strength is that this tool allows the doctor and
patient to review in a quantitative sense the benefits and risk of
different options. The limitations are that for many therapies we have
limited knowledge about their long-term efficacy (and Adjuvant! makes
specific assumptions to deal with this), and undoubtedly we will learn
more about how some tumors’ characters may affect their sensitivity to
therapy. How new prognostic factors and genomic information may be
included will be discussed.
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In 1975 we presented our first report on the efficacy of cyclophos-
phamide, methotrexate and fluorouracil (CMF) as adjuvant treatment for
node-positive breast cancer. Thirty years later, the results of this study
demonstrate that the significant advantage in both relapse-free
(reduction in relative risk for relapse of 29%) and overall survival
(reduction in relative risk for death of 21%) persists over the years and
that adjuvant CMF can exert a moderate but worthwhile suppression of
micrometastases, regardless of anatomical sites [1].
With the aim of further improving the prognosis of operable breast
cancer patients, in the early 1980s many research groups designed
and carried out new randomized trials including anthracyclines. Despite
the fact that many individual trials failed to observe a true benefit for the
tested anthracycline regimen, the arithmetic construction on which the
international overview is based (i.e. the summing up of many individual
trials to increase the statistical power) allowed it to be estimated that
there was a reduction in the risk for disease relapse and death of
approximately 10%, corresponding to an absolute difference of
approximately 3% [2].
At the Milan Cancer Institute we designed two different studies to test
the effectiveness of sequential non-cross-resistant regimens containing
anthracyclines. Briefly, in patients with moderate risk for relapse the
sequential delivery of CMF followed by adriamycin was compared with
CMF alone, whereas in a second study conducted in high-risk patient
the inverse sequence (adriamycin followed by CMF) was tested. The
rationale behind these studies was that switching to another regimen
early in the administration of chemotherapy could overcome drug
resistance. The updated 20-year results confirmed that the relative
merits of anthracycline-containing adjuvant programs can also depend
on the modality of administration and must be assessed in properly
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designed trials in which the magnitude of the benefits can be weighted
against potential risks [3].
The treatment results observed after sequential adriamycin followed by
CMF in a poor risk subset could probably be explained by an increased
density of the anthracycline, which was delivered at full dose within the
first 9 weeks of treatment. The value of dose density was recently
confirmed by the National Cancer Institute’s Breast Intergroup INT
C9741 trial, in which patients who received the dose-dense regimens
had significantly improved early treatment outcome compared with their
counterparts who did not receive these regimens.
The role of sequential non-cross-resistant regimens was tested in many
other trials, both in the adjuvant and neoadjuvant settings. Of note, the
3-year joint efficacy analysis of the National Epirubicin Adjuvant Trial
(NEAT) and of the Scottish Cancer Trials Breast Group reported a
highly significant benefit in favor of the sequential regimen, supporting
the hypothesis that the sequential administration of single-agent
anthracyclines given upfront before CMF can indeed improve treatment
outcome. Also, the addition of taxanes after delivery of adriamycin and
cyclophosphamide contributed to improving therapeutic results over the
nontaxane regimen both in the adjuvant and neoadjuvant settings. By
contrast, in the INT C9741 trial no difference was detected in treatment
outcome between the concurrent or sequential schedules of adriamycin,
cyclophosphamide and paclitaxel. Similarly, the MD Anderson
randomized study failed to detect superiority of the sequential arm.
Thirty years ago, treating patients who were free of identifiable
metastatic disease with systemic adjuvant therapy because some of
them might eventually develop distant disease was a revolutionary
departure from prior treatment approaches [4]. It has been estimated
that improvements since the 1970s in the way in which breast cancer
is managed must have prevented about 25–30% of the breast cancer
deaths in middle-aged women that would otherwise have occurred in
the year 2000.
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Introduction After standard-dose chemotherapy (SDC), more than
50% of patients with HRPBC (defined as extensive axillary node
involvement or inflammatory disease) experience relapse. Controversy
has surrounded the use of HDC for HRPBC for over a decade. Current
results from at least 15 randomized trials comparing diverse forms of
HDC and SDC for HRPBC appear contradictory at this point [1]. In
addition, some studies suggest that younger women might benefit
selectively from HDC. An NCI-sponsored meta-analysis is in progress.
Regardless of this unsettled issue, it is clear that a substantial
percentage of HRPBC patients still relapse after HDC. Extensive
prognostic studies are required to improve their outcome. Such
investigations may allow us to identify adequate patient subsets and
new therapeutic targets for trials of developmental therapeutics.
Combinations of HDC, capable of ample cytoreduction, with novel
agents that target specific tumor features responsible for post-
transplant relapse may hold promise.
Methods We analyzed clinical variables in HRPBC patients enrolled at
the University of Colorado in clinical trials of HDC targeting 4–9+, ≥10+
nodes, or inflammatory disease. First, we developed a prognostic model
among 176 patients treated from 1990 to 1997, and validated it in an
external sample. Subsequently, the model was validated prospectively in
a second cohort of 88 patients treated at Colorado since 1997.
We hypothesized that intrinsic biologic differences, insurmountable by
HDC, existed between the two risk categories identified by the clinical
model. Through immunohistochemical analyses of paraffin-embedded
tumor blocks collected from the referring institutions, we studied a
series of putative molecular candidates, related to signal transduction
pathways or an angiogenic phenotype, which could be responsible, at
least in part, for those differences.
Results At median follow up of more than 7 years, the relapse-free
survival (RFS) and overall survival (OS) rates for the whole group of
264 patients treated at Colorado were 69.8% and 73%, respectively.
The median time to relapse was 14 months (63.5% relapses within the
first 2 years, 6.7% after the 5th year).
We identified three clinical variables independently associated with
outcome: nodal ratio (number of involved nodes /number of dissected
nodes), pathological tumor size, and hormone receptors [2]. A scoring
system was constructed with those variables: score = (nodal ratio ×
3.05) + (tumor size × 0.15) – (ER/PR × 1.15). In this formula, size is
entered in cm, and ER/PR is assigned ‘1’ if positive (estrogen receptor
[ER] and/or progesterone receptor [PR] positive), or '0' if negative
(both negative). A cutoff score of 2.41 yields the best sensitivity and
specificity. Thus, patients with low (<2.41) and high (≥2.41) scores
before transplant presented significant differences in outcome. This
model was validated in an external sample of 225 HRPBC patients
treated at Duke University with the same HDC. It was subsequently
validated prospectively in our second patient cohort [3].
Overexpression of HER2, identified as an independent predictor of
outcome, complemented the clinical model, establishing the following
risk groups: low risk (low score, HER2-negative; 44% patients; 87%
RFS), intermediate risk (low score, HER2-positive; 29% patients; 68%
RFS), high risk (high score, any HER2; 27% patients; 49% RFS) [4].
We detected an independent prognostic effect of EGFR (epidermal
growth factor receptor), particularly among HER2-positive patients [5],
which suggests a synergistic effect through heterodimerization of both
receptors. In contrast, we did not observe a prognostic effect of p53
status [4].
Tumor angiogenesis, assessed through CD31-stained microvessel count,
was an independent adverse predictor of outcome [6]. In contrast, tumor
VEGF (vascular endothelial growth factor) expression lacked prognostic
significance in our population with locoregionally advanced tumors, in
contrast to multiple prior observations in patients with earlier disease [6].
Finally, we observed that the presence of tumor cells contaminating the
apheresis product, detected through immunocytochemistry for cyto-
keratins, was independently associated with post-transplant relapse [7].
Conclusions We can now predict which HRPBC patients are most likely
to remain long-term disease free after HDC. Additionally, we identified
important prognostic molecular markers that could constitute relevant
targets for studies combining novel therapeutics with HDC in HRPBC.
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Introduction The role of high-dose chemotherapy in the adjuvant
treatment of high-dose breast cancer has not been established.
Results have been reported from six randomized studies with a
symmetrical study design (Table 1). All show a lower relapse rate in the
high-dose arm, but in only one study was this result statistically
significant.
Methods Patients below 56 years of age who had undergone surgery
for stage II or III breast cancer were eligible if they had at least four
tumor-positive axillary lymph nodes. Patients in the conventional dose
(CD) arm received five courses of FEC (fluorouracil 500 mg/m2,
epirubicin 90 mg/m2 and cyclophosphamide 500 mg/m2; every
3 weeks) followed by radiation therapy and tamoxifen. The high-dose
(HD) arm was identical, except that high-dose chemotherapy (CTC
[cyclophosphamide 6 g/m2, thiotepa 480 mg/m2 and carboplatin
1600 mg/m2]) with peripheral blood progenitor cell reinfusion was
given instead of the fifth FEC course.
Results Between August 1993 and July 1999, 885 patients with
primary breast cancer and four or more tumor-positive lymph nodes
were randomized in 10 Dutch centers in a study of high-dose
chemotherapy. The results of this study at 57 months of follow-up have
now been updated at 87 months. In a pathology review, 621 tumor
samples were shown to be HER2/neu-negative (either 0+ at
immunohistochemistry or negative at in situ hybridization). Patients with
HER2/neu-negative disease had a 5-year RFS of 72% following HD and
of 59% after CD (P = 0.002). Overall survival in the HD group was 78%
at 5 years versus 71% for the CD group (P = 0.02). Young age and low
malignancy grade were associated with a relative benefit for HD (tests
for interactions: P = 0.04 and P = 0.0057, respectively). The treatment-
related mortality in the high-dose chemotherapy arm was 1%. An equal
number of second malignancies were observed in both arms.
Conclusion Although the subgroup analysis of HER2/neu-negative
disease was not planned in the original protocol, these findings are
consistent with findings from other studies [4]. The marked efficacy of
HD therapy in HER2/neu-negative breast cancer may have been
masked in this and in other studies by its disadvantage in the
HER2/neu-positive group, which may have benefited from a higher
dose of anthracycline-dose in the control arm. High-dose alkylating
chemotherapy is a viable option for high-risk breast cancer patients
with HER2/neu-negative disease.
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Table 1 (abstract S23)
Randomized studies evaluating the role of high-dose chemotherapy in high-risk breast cancer
Author Patients Selection Conventional arm High-dose arm RFS analysis
Rodenhuis [1] 885 4+ nodes 5×FEC 4×FEC – CTC HD better (P = 0.08)
Peters [2] 785 10+ nodes 4×CAF + ID-CPB 4×CAF + HD-CPB No difference, HD fewer relapses
Tallman [3] 540 10+ nodes 6×CAF 6×CAF + CT No difference, HD fewer relapses
Roché 314 8+ nodes 4×FEC 4×FEC + CMA HD better (P = 0.002)
Tokuda 97 10+ nodes 6×CAF 6×CAF + CT HD better (NS)
Rodenhuis 81 Infraclav biopsy 4×FEC 4×FEC + CTC No difference, HD less relapses
CAF, cyclophosphamide, doxorubicin, fluorouracil; CMA, cyclophosphamide, mitoxantrone and melphalan; CT, cyclophosphamide and thiotepa; CTC,
cyclophosphamide, thiotepa and carboplatin; FEC, fluorouracil, epirubicin, cyclophosphamide; nodes, tumor-positive axillary lymph nodes; HD-CPB, high-dose
cyclophosphamide, cisplatin and BCNU; ID-CPB, intermediate-dose cyclophosphamide, cisplatin and BCNU.
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Introduction Primary carcinoma of the breast is a worldwide public-
health problem; despite conventional treatment, long-term prognosis is
poor, especially for large tumors or in cases with axillary involvement. In
an attempt to improve these results, phase II high-dose chemotherapy
trials were performed by the SOLTI Group.
Method A total of 416 patients were included in three high-dose
chemotherapy trials in the adjuvant setting, as follows. The 9301 trial
included 297 patients with stage II/III breast carcinoma with more than
10 axillary lymph nodes involved. After conventional adjuvant chemo-
therapy (FEC regimen), high-dose chemotherapy (STAMP V regimen)
with peripheral stem cell support was performed. The 9302 trial
included 66 patients with inflamatory breast carcinoma treated with
three to six cycles of FEC neoadjuvant therapy. Responding patients
were treated with high-dose chemotherapy after surgery with STAMP V
regimen and blood stem cell support. The 9702 trial included 53
patients with stage III breast cancer treated with neoadjuvant
doxorubicin and paclitaxel. Patients with pathologic axillary involvement
in the surgical specimen were treated with adjuvant STAMP V high-
dose chemotherapy.
Results In trial 9301, with a median follow up of 63 months, 5-year
disease-free survival (DFS) was 59% and overall survival (OS) was
80%. In trial 9302, median DFS was 30 months and median OS 75
months, with 55.3% of patients alive at 5 years. In trial 9702, with a
median follow up of 31 months, the median DFS and OS have not yet
been determined. No toxic deaths were reported. Most common
nonhematological toxicities were emesis, mucositis, hepatic and
alopecia. Neutropenia was easily resolved with G-CSF support; and
anemia and trombopenia were frequent (50–60% patients).
Conclusion The toxicity of treatment with high-dose chemotherapy is
acceptable and similar to that described in other series. Although the
results obtained are promising, their comparison with historic controls
and the information derived from other reported trials do not enable us
to recommend high-dose chemotherapy with bone-marrow rescue as a
routine treatment in high-risk breast cancer. It nevertheless remains a
valid investigational strategy.
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Introduction A new oral formulation of vinorelbine has been introduced
in clinical studies since 1994, following increasing interest in the
development of oral chemotherapy, driven by pharmacoeconomic
issues, patient convenience and the potential for improved quality of
life. A dose-finding study [1] established that 100 mg/m2 was the MTD
dose, limiting toxicities being neutropenia, nausea and vomiting, and
neuroconstipation; the recommended dose was then defined at
80 mg/m2 per week. The first phase II studies conducted in chemo-
therapy-naive NSCLC and as first-line chemotherapy in advanced
breast cancer (ABC) showed an excessive rate of complicated
neutropenia. This led to the formulation of a new schedule in which a
lower dose of 60 mg/m2 per week was administered for the first three
courses with escalation to 80 mg/m2, with a safety profile qualitatively
comparable to that of intravenous vinorelbine at standard doses [2].
Equivalent blood concentrations were demonstrated between
80 mg/m2 oral and 30 mg/m2 intravenous, and between 60 mg/m2 oral
and 25 mg/m2 intravenous [3].
Studies in metastatic breast cancer (MBC): single agent A
multicenter phase II trial assessed the activity, safety and
pharmacokinetic profile of oral navelbine in ABC. Sixty-four patients
were entered to receive oral NVB on a weekly basis for a total of
8 weeks unless progression or toxicity occurred. Oral vinorelbine was
given at 60 mg/m2 weekly for the first three administrations and was
increased to 80 mg/m2 for the subsequent administrations if there was
no grade 4 neutropenia or no more than one episode of grade 3
neutropenia. Patients with objective response or stable disease
continued treatment up to a total of 12 weeks or more. Fifty-eight
evaluable patients were included. Four patients (6.9%) had complete
responses and 14 (24.1%) had partial responses, for an overall
response rate of 31% (95% confidence interval 19–43%). The median
progression-free survival was 17.4 weeks, and the median overall
survival was 22.9 months. There were no treatment-related deaths. The
main toxicity was neutropenia: grade 4 in 17.2% of the patients, and
1.8% of administrations and associated clinical serious events in four
patients (6.2%). Grade 3 and 4 nausea and/or vomiting were noted in
3.1% and 4.6% of the patients, respectively. Only one patient
developed grade 3 neuroconstipation. An analysis of Quality of Life
Questionnaire C30 forms revealed no significant alteration between
baseline and weeks 8 and 16 in global quality of life. Oral navelbine as
single agent in first-line MBC has the same efficacy of intravenous
vinorelbine in phase II studies in terms of OR, duration of response,
progression-free survival and overall survival, and is well tolerated with
a manageable gastrointestinal toxicity (8% of G3-4 N/V without
prophylactic antiemetic treatment) [5].
A second phase II trial is still ongoing. An interim analysis on the first
72 patients (median age 63 years) showed a similar toxicity profile with
a RR of 30%, a median progression free-survival of 4.6 months and a
median survival of 20.7 months.
Studies in MBC: combinations The increasing prevalence of
antracycline and taxane treatment in adjuvant setting led to an
exploration of new combinations of non-cross-resistant therapies, in
particular for those patients for which a polychemotherapy might offer
greater benefits than single agents. In this setting the results of
intravenous navelbine in combination with other drugs suggested new
models in which to introduce the oral formulation.
Several phase II studies had investigated intravenous vinorelbine in
association with capecitabine with a RR in second line >50% and with
a mild toxicity. Only one phase II trial with this combination has been
conducted as first-line chemotherapy, and it confirmed a good toxicity
profile. The availability of oral formulations of both of these drugs led to
investigation of their attractive combination, and preliminary results are
now available from an ongoing phase II trial of vinorelbine oral plus
capecitabine ± trastuzumab in MBC as first-line chemotherapy.
Capecitabine is administered at the dose of 2000 mg/m2 per day given
days 1 to 14, and vinorelbine at the dose of 60 mg/m2 on days 1 and 8
every 3 weeks for the first course, then escalated to 80 mg/m2 from the
second course. After 81 courses the incidence of G3 nausea/vomiting
was 2.5%, G3 diarrhea 3.7%, grade 3 HFS 1.2%, and G3/4
neutropenia 13.5%. After 2 cycles the combination has revealed 4/16
CR-PR, 10/16 SD and 1/16 PD; and after 4 cycles 7/15 CR-PR and
7/15 SD. From these preliminary results this combination seems to be
effective in the treatment of MBC previously treated with an
anthracycline and/or a taxane with low toxicity.
Several studies have investigated the combination of intravenous
navelbine and trastuzumab with an OR of 61–75%, demonstrating that
this can be an effective and well tolerated option for HER2+ MBC. It is
Available online http://breast-cancer-research.com/supplements/7/S1
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an important regimen, given the increasing prevalence of antracycline
and taxane treatment in adjuvant setting.
Other sequential combinations of oral vinorelbine with paclitaxel or
docetaxel or epirubicin are being explored, suggesting a possible role
for the oral formulation in a sequential prolonged treatment in MBC.
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Currently, breast cancer is the primary reason for death due to cancer
in Spanish women aged between 35 and 64 years. Nevertheless,
despite detecting an increased incidence, it is observed a decrease on
mortality rates, in agreement with it is observed in other European
countries. This issue is basically due to the development of programs
to sift and the use of widespread systemic treatments, both on early
and advanced stages of the disease. During the past decade breast
cancer has benefited from incorporation of new antitumor drugs to
treat this kind of cancer. These new drugs are able to control, in an
effective way, the progress of metastatic disease and slow down or
eradicate micrometastasis in early stages.
Patients with metastatic disease have been useful in the study of new
active agents and their combinations subsequently used in adjuvant
regimens. Breast cancer treatment often achieves important objective
responses with different durations of treatment, but these durations
have an impact on patient survival. The median of survival in this group
varies between 18 and 24 months, and the main objective for the
treatment of metastatic breast cancer is palliation by means of the
control of disease-related symptoms, with an adequate profile of
toxicity, which provides an improvement in quality of life.
There are currently several lines of work on the development of breast
cancer treatments at different stages. These are expected to improve
survival and quality of life parameters. These lines of development
range from the incorporation of new active agents (cytotoxic and
hormonal) to optimization of current schemes with active agents (old
and new), by means of new combinations used for metastatic disease
and use in early stages, even before surgery.
Breast cancer is one of the most chemo sensible solid tumours, that
respond to almost every cytotoxic drug used alone or in combination.
These active agents include alkylating drugs (e.g. cyclophosphamide
and the cisplatins) and antimetabolites (e.g. fluorouracil and
methotrexate), which were used for the design of the first-line
polychemotherapy schemes in solid tumours such as CMF. After this,
the anthracyclines (doxorubicin and epirubicin) were substituted for
methotrexate in the latter combination, giving us the FAC and FEC
schemes, which were classic treatments until relatively recently. During
the past decade, many new agents have been incorporated that have
improved both response rates and patient survival, such as the taxanes
(paclitaxel and docetaxel), vinorelbine, caelyx and, recently,
gemcitabine; there have been used in new combinations or have even
been used as isolated agents as second- and third-line treatments for
with advanced disease.
The main problem with these agents and their combinations is the
complexity of administration, at day hospitals and through intravenous
injections, which seriously impairs patient quality of life. However, the
benefit in terms of survival parameters and symptom reduction offset
these difficulties.
Capecitabine (Xeloda), one of the most recently introduced active
agents into treatment for metastatic breast cancer, has the same
antitumoral activity as current agents but without many of their
inconveniences, which is the reason why its incorporation into standard
treatment for breast cancer patients is becoming increasingly common.
It is orally administered, avoiding the difficulties associated with
intravenous injection. Its mode of action is similar to that of 5-
fluorouracyl in continuous infusion, without the need for infuser or
central catheters. On the other hand, it has a synergistic action with the
majority of cytotoxic drugs, in particular with docetaxel, leading to a
better survival rates. The results of studies conducted in recent years
have confirmed the important role of capecitabine in the treatment of
advanced disease, and it have been the base for the studies with
capecitabine on the adjuvant and neoadjuvant setting.
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In the past few years breast cancer mortality has been declining in
most Western countries as a consequence of better education,
implementation of screening programs and more effective therapies.
However, a small proportion of patients are metastatic at initial
diagnosis (about 5–7%), and 25–30% of patients develop metastases
following primary treatment. At this stage, the disease is considered
incurable, the median survival ranges from 2 to 4 years, and a limited
proportion of patients (about 20%) survive more than 5 years. In this
scenario, it is important to identify the aims of treatment on the basis of
individual patient needs. Data from clinical trials, meta-analyses,
databases of large institutions, and cancer registries indicate that
chemotherapy can prolong survival, and survival prolongation is
associated with the activity of drugs [1-5]. Moreover, those patients
who achieve a complete response have about 20% chance of surviving
beyond 5 years [6]. Finally, although there are few trials specifically
addressing symptomatic control and quality of life, it is generally agreed
that tumor shrinkage is associated with better control of symptoms,
and that quality of life results from the balance between activity and
tolerability of treatments.
Metastatic breast cancer patients represent a very heterogeneous
population, and several factors are important in determining prognosis:
patient characteristics such as motivation, compliance with treatment,
age, performance status and comorbidities; tumor characteristics such
as hormonal receptor status and expression of HER2-neu; prior
adjuvant therapies and disease-free interval; and site and extension of
metastatic spread.
Treatment options include locoregional treatments, endocrine agents,
monoclonal antibodies, bisphosphonates and cytotoxic agents. The
aims of these treatments include symptomatic control, maintenance of
quality of life, tumor shrinkage, prolonging time to progression, and
survival prolongation.
Although the role of radiation therapy in controlling locoregional
relapses, and of endocrine therapy in the upfront treatment of
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endocrine-sensitive tumors is undebatable, the optimal use of cytotoxic
chemotherapy remains controversial. The main reasons for the lack of
general consensus are the heterogeneity of the patient population and
the availability of several effective options. In the following paragraphs
we discuss the different treatment options in the most common clinical
scenarios.
Treatment options based on patient characteristics The majority of
metastatic breast cancer patients are over 65 years of age, and
therefore a significant proportion are affected by comorbidities such as
hypertension, diabetes and respiratory disease [7]. Tolerability of
chemotherapy can be profoundly influenced by these comorbidities as
well as by their specific treatments.
In the case of elderly patients with significant comorbidities and
declining general condition, the aim of treatment is symptomatic control
with improvement in quality of life (QoL). To date, the availability of oral
agents such as capecitabine and navelbine allows for a good balance
between activity, tolerability, compliance and dosage flexibility. Further-
more, weekly administration allows maintenance of the activity of
important cytotoxic agents such as taxanes and platinum salts with
substantial decrease in toxicity. Finally, new antimetabolites
(gemcitabine) or new formulations of old drugs (liposome-encapsulated
doxorubicin) are generally associated with reduced toxicity. For these
patients it is clear that the best choice is the use of single agents that
can be sequentially administered on the basis of tolerability and
disease control.
About 20% of patients present with locoregional relapses (regional
lymph nodes, skin metastases). Moreover more sensitive imaging
techniques (Multislice computed tomography [CT], magnetic resonance
imaging [MRI], positron emission tomography [PET] scan) and the
development of methods to detect micrometastatic disease (i.e.
circulating tumor cells) permit diagnosis of an increasing proportion of
patients with oligometastatic disease. A reasonable percentage of
these patients can be cured or at least rendered disease free for
prolonged period of time; a chemotherapy regimen to induce rapid and
important tumor shrinkage followed by locoregional treatments
(radiotherapy, surgery, radiofrequency ablation) is necessary to achieve
this goal. In this setting, it is clear that combination regimens should be
the preferred option.
Another clinical scenario is represented by younger patients, without
comorbid conditions, and massive visceral involvement. Here again,
rapid tumor shrinkage is important in preventing life-threatening organ
failure. In this setting, combination regimens ensure a higher percentage
of objective responses [8,9] and a shorter time to response [10].
Treatment options based on tumor characteristics Breast cancer
tumors are at least as heterogeneous as breast cancer patients.
However, the only tumor-related parameters currently utilized in the
decision making process are the disease course in the individual
patient, hormone receptor status, and HER2-neu overexpression.
In the case of patients with slowly-growing hormone receptor-negative
tumors and predominant bone disease, main aims of treatment are
maintenance of QoL and prolonging time to progression. In these
cases, single-agent chemotherapy provides a better balance between
activity and tolerability. More frequently, patients with hormone-
sensitive tumors receive several lines of endocrine therapy until
development of hormone resistance. Here again, when chemotherapy
is required, the preferred choice is the sequential administration of
single agents.
Another important tumor characteristic is the HER2-neu status; HER2-
neu is overexpressed in 25–30% of breast cancers. As a single agent
trastuzumab, a monoclonal antibody directed against the extra-
membrane portion of HER2 receptor, can induce a 30% response rate
in HER2-overexpressing tumors. The addition of trastuzumab to
chemotherapy as compared with chemotherapy alone is associated
with a significant improvement in objective response rate, duration of
response and overall survival [11].
Several cytotoxic agents showed synergism or additive effect when
combined with trastuzumab; clinical trials have shown that trastuzumab
can successfully be combined with both single agent and combination
chemotherapy.
Treatment options based on prior adjuvant therapy Anthracyclines
represent the most active agents, and anthracycline-containing
regimens are more effective in terms of response rates, complete
remission rates, remission duration and survival. However, anthracycline
regimens are increasingly used in the adjuvant setting, and therefore
retreatment with anthracyclines, even if effective, is limited to patients
exposed to low cumulative anthracycline doses and with a relapse-free
survival after adjuvant chemotherapy longer than 12 months. The main
limitation to anthracyclines is their dose-dependent cardiac toxicity;
patients should not exceed the cumulative dose of 450–550 mg/m2 for
doxorubicin and 800-900 mg/m2 for epirubicin. However, few data are
available on the efficacy of anthracycline rechallenge after prior
exposure to adjuvant anthracycline. A recent report from our group [12]
has shown that anthracycline–taxane combinations as first-line
treatment for metastatic breast cancer are effective, regardless of
previous adjuvant chemotherapy.
As more and more patients are receiving taxanes as a component of
their adjuvant program, it will be important also to have data on the
efficacy of taxane rechallenge in metastatic patients.
Conclusion Survival prolongation must be the primary goal of
treatment, and this aim can be achieved with the incorporation of new
active agents in the treatment strategy. Both combined and sequential
single agents are acceptable options; however, if not contraindicated
by the conditions of the patient and if feasible with an acceptable
toxicity profile, there is no reason to delay the upfront use of active
agents.
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Introduction Patients with metastatic breast cancer have a highly
variable clinical course. Systemic chemotherapy may decrease
symptoms and prolong survival for some patients. However, others
experience significant toxicity and achieve little benefit. Predictive
markers are needed to determine which patients will benefit from
particular chemotherapy agents and which should be offered novel
therapeutics.
Methods The English literature related to predictive markers for
metastatic cancer was reviewed. Translational studies examining the
potential role of tumor profiles in the selection of optimal chemotherapy
agents were identified. Particular attention was paid to studies
examining sensitivity and resistance to anthracyclines, taxanes,
vinorelbine and capecitabine.
Conclusion This paper will summarize the rapidly expanding data
published to data and will discuss clinical trial designs that will facilitate
future studies.
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Introduction The efficacy of aromatase inhibitors varies widely among
postmenopausal breast cancer patients, but it is not associated with
aromatase gene expression. We evaluated whether polymorphisms of
the aromatase gene CYP19 are related to the efficacy of the aromatase
inhibitor letrozole.
Methods PCR allelic discrimination was used to examine single
nucleotide polymorphisms (SNPs) in DNA obtained from 67 breast
carcinomas. Postmenopausal patients with hormone receptor positive
metastatic breast cancer were treated with the aromatase inhibitor
letrozole. All patients in the study had documented disease
progression before receiving letrozole, and had been treated previously
with tamoxifen or another selective estrogen receptor modulator
(SERM). Sixty-five patients were evaluable for efficacy. Three regions of
the aromatase CYP19 gene were examined: two were localized in the
3’ untranslated region (UTR; rs10046 and rs4646) and one in the
intronic region (rs727479). Presence of variant gene polymorphisms
was correlated with the efficacy end-point of the study, which was time
to treatment progression (TTP).
Results The median age of patients was 62 years, and the median
number of metastatic sites was two. Median TTP was 12.1 months.
Percentage of cases with allelic SNP variation of rs10046 was 69%, of
rs4646 was 48%, and of rs727479 was 63%. TTP was significantly
longer in patients with the rs4646 variant of CYP19 when compared with
normal CYP19 (17.2 months versus 6.4 months; P = 0.02). A relationship
of TTP with the rs10046 or rs727479 variant was not observed.
Conclusion In hormone receptor positive metastatic breast cancer
patients treated with the aromatase inhibitor letrozole, the presence of
a SNP on the 3’-UTR of the CYP19 aromatase gene is associated with
improved treatment efficacy, and may help in the future to select
patients for antiaromatase therapy.
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Metastases to osseous structures represent the most common
metastatic destination for human breast carcinoma. Conversely, breast
cancer is one of the most common sources of bone metastases. Bone
metastases produce multiple complications, including pain, patho-
logical fractures, hypercalcemia, and spinal cord compression. Some of
these complications are potentially catastrophic and all reduce the
quality of life of patients with metastatic breast cancer.
Analgesics, orthopedic surgery, and radiotherapy have been consi-
dered the only successful approaches to the management of complica-
tions of bone metastases prior to the therapeutic development of bis-
phosphonates. Research over the past decade expanded our under-
standing of the metastatic process, including the pathophysiology of
bone metastases. Cancer cells play a minor role in the direct process
of bone metastases. Rather, cancer cells produce and secrete a variety
of growth factors (transforming growth factors ∀ and ∃, epidermal
growth factor, granulocyte–macrophage colony-stimulating factor) as
well as a number of cytokines (tumor necrosis factor, IL-1 and IL-6,
prostaglandins) and parathyroid hormone-related protein (PTHrP),
which recruit osteoclast precursors and activate mature osteoclasts. It
is the excessive osteoclastic activity, uncoupled from matched
osteoblastic activity, that results in excessive bone resorption and bone
metastases. Therefore, efforts at interfering with osteoclast activation,
maturation and the recruitment of osteoclast precursors have become
the main focuses of therapeutic research in the area of bone
metastases.
A variety of substances have been shown to inhibit osteoclast activity;
calcitonins, gallium nitrate and bisphosphonates have marked thera-
peutic effects in the management of hypercalcemia of malignancy,
Paget’s disease of bone, and bone metastases. Bisphosphonates are
considered the standard of care for all these indications. Clodronate,
pamidronate, ibandronate, and zoledronic acid have all been shown to
reduce bone-related events in randomized trials, including fractures,
pain, hypercalcemia, and spinal cord compression. In addition, the
systematic use of bisphosphonates, especially IV aminobisphos-
phonates (pamidronate, zoledronic acid), was also shown in placebo-
controlled trials to reduce the need for radiotherapy and orthopedic
surgery. Therefore, current practice guidelines indicate initiation of
monthly intravenous bisphosphonate therapy upon the identification of
bone metastases by imaging, regardless of other anticancer treatment
being administered. Bisphosphonate therapy should continue
indefinitely, with periodic monitoring of renal function.
In patients with primary breast cancer, the use of bisphosphonate
therapy for prevention of bone metastases is not indicated outside of a
clinical trial. There are conflicting results from three, relatively small,
randomized trials regarding the clinical utility of adjuvant
bisphosphonate therapy. Ongoing and planned randomized trials in the
adjuvant setting should determine the contribution, if any, of
bisphosphonates to the management of primary breast cancer. In this
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regard, NSABP B-34 has completed accrual, and results should be
available within the next 1–2 years.
A different indication for bisphosphonates, independent of the
presence or absence of breast cancer, is for management of
osteopenia or osteoporosis. National and international guidelines exist
for postmenopausal patients, and patients with breast cancer should
be monitored and treated for osteoporosis in the same manner.
Because some of the anticancer treatments used to manage breast
cancer result in premature ovarian ablation or suppression resulting in
rapid bone loss, early assessment of bone density in these patients is
necessary to determine the role of bisphosphonate therapy to preserve
bone strength and density.
A clearer understanding of signaling pathways involved in osteoclast
activation and uncoupled and unmatched bone resorption associated
with malignant tumors has led to the development of several new
strategies to manage metastatic bone disease. Osteoprotegerin, and
antibodies directed to the ligand or the receptor activator of nuclear
factor-κB, have demonstrated substantial activity in inhibiting
osteoclast activation, recruitment and differentiation. Phase II and III
trials with some of these agents are progressing rapidly.
PTHrP is a critical initiating factor in the process of bone resorption
and it is produced by a number of malignant tumor cells, including
breast cancer. Antibodies against PTHrP are being explored as
therapeutic agents in advanced clinical trials.
Src inhibitors might have an important role to play in inhibiting
osteoclast activation, and several lead compounds are initiating their
clinical evaluation alone and in combination with other relevant
treatments.
The management of bone metastases has benefited enormously by our
expanded understanding of basic biological processes related to
osteoclast and osteoblast function. These advances will result in
improve management of established bone metastases and possibly
effective preventive interventions.
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Cyclo-oxygenase-2 expression is associated with
poor clinical outcome after doxorubicin-based
chemotherapy in node-positive breast cancer:
integration of tissue microarray
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Introduction We performed this study to evaluate the frequency and
clinical implications of cyclo-oxygenase (COX)-2 expression in clinical
breast cancer.
Method COX-2 expression was analyzed on tissue microarray (TMA)
of 178 node-positive patients treated with doxorubicin-based adjuvant
chemotherapy by immunohistochemistry (IHC).
Results COX-2 was over-expressed in 70 (39.3%) out of 178 invasive
breast cancers. COX-2 expression was significantly increased in
undifferentiated tumor with high S-phase fraction. COX-2 expression
appeared to be increased in HER2-amplified tumors but the difference
was not statistically significant. There was no significant association
between COX-2 over-expression and other clinical and biologic
profiles such as tumor size, histologic grade, and oestrogen receptor
(ER) expression. Disease-free survival (DFS) and overall survival (OS)
of the patients with COX-2 expressing tumor was significantly
decreased compared with the patients with COX-2 negative tumor
(P = 0.009 for DFS, P = 0.011 for OS). Cox-2 expression and
histologic grade were significant prognostic factors for DFS and OS in
multivariate analysis.
Conclusion The intimate association of COX-2 expression with
increased S-phase and high histologic grade, together with poor
clinical outcomes for COX-2 expressing tumors, indicates that COX-2
expression represents a highly aggressive phenotype of breast cancer.
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Predictors of positive axillary lymph nodes in breast
cancer patients with metastatic sentinel lymph node
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J Faria1, J Weinholtz1, S André3, C Costa1, O Almeida3, 
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Introduction Breast cancer with metastatic sentinel lymph nodes
(SLN) may have clinicopathologic factors associated with the presence
of positive nonsentinel axillary nodes (NSLN). The aim of the present
study was to determine factors that predict involvement of NSLN in
breast cancer patients with positive SLN.
Method A prospective database search identified 80 patients who
underwent SLN biopsy for invasive breast cancer between January
1999 and August 2002. Clinicopathologic data were analyzed to
determine factors that predicted additional positive axillary nodes.
Results A total of 23 patients had positive SLN and underwent
conventional axillary lymph node dissection. Statistical analysis
revealed that lymphovascular invasion (P ~ 0.00000), SLN metastasis
>2 mm (P = 0.002), and the presence of extranodal involvement
(P = 0.002), were positive predictors of the metastatic involvement of
NSLN.
Conclusion The likelihood of positive NSLN correlates with pathologic
parameters such as the presence of lymphovascular invasion, size of
the SLN metastasis, and extranodal involvement. These data may be
helpful with the regard to the decision to undertake axillary dissection in
breast cancer patients with metastatic SLN.
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Fibroadenoma of breast in Iranian women between
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A Abdollahi1, S Shalbaf2
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Introduction Fibroadenomas are the most common benign tumors of
the female breast and are associated with a slight increase in risk for
subsequent breast cancer. The aim of this study was to make a
methodical inventory of risk factors for fibroadenoma in women.
Materials and method This study was conducted between 1994 and
2004 in cross-section in 4000 women hospitalized in some Iranian
hospitals for fibroadenoma. In the study the following factors were
examined: age, menstrual cycle pattern, age of menarche, menopause
after 50 years, oral contraceptive use, mastalgia, marriage, number of
full-term pregnancies, first pregnancy over age 35 years, history of
breastfeeding, cigar smoking, the kind of radiology for diagnosis, the
place of tumor, tumor location in breast, diameter of tumor, multiple
tumor, patient background and family history of fibroadenoma, and
pathology report.
Results The common age was between 26 and 30 years; 42% had
bleeding for more than 35 days; 57.8% had menarche before 12 years
old; 2.6% had menopause after 50 years old; 67.3% of patients used
oral contraceptive; 57% had premenstrual mastalgia; 11.9% were
single; the risk for fibroadenoma decreased with increasing number of
full-term pregnancies; 10.2% had first pregnancy at age over 35 years;
36.4% had breastfed; 7.9% had smoked cigarettes; 36.9% of patients
had only mammography, 82.1% only had sonography examination, and
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28.9% had both; the left breast was affected slightly more than the
right; the most frequent location was the upper-outer quadrant; the
most frequent size was between 4 and 5.9 cm; 24.7% had multiple
tumors; 12.2% had background and 62.9% had family history of
fibroadenoma; 17.6% had malignancy in their pathology report.
Conclusion The results for the studied risk factors for fibroadenoma
are similar to those of studies conducted in other countries. In our
study, however, we observed some differences in breastfeeding,
cigarette smoking, patient background, and malignancy in the
pathology report.
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Nanoparticulate paclitaxel loaded into sterically
stabilized mixed phospholipid micelles to improve
chemotherapy of breast cancer
I Rubinstein, A Krishnadas, LR Peddakota, H Önyüksel
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Active targeting of water-insoluble chemotherapeutic drugs, such as
paclitaxel, to breast cancer is a highly desirable because of its
associated increase in anticancer efficacy coupled with reduced
systemic drug toxicity. However, rational design of these drug delivery
platforms should take into account both pathobiological attributes of
breast cancer, such as enhanced permeability and retention
phenomenon and overexpression of vasoactive intestinal peptide (VIP)
receptors, as well as biophysical properties of its ingredients, including
ease of preparation, water insoluble drug loading capacity, steric
hindrance, nanosize, and scale-up production and storage. To this end,
we developed and tested a novel biocompatible and biodegradable
nanoparticulate formulation of VIP-conjugated sterically stabilized
phospholipid mixed micelles (SSMM-VIP; size ~14 nm) composed of
disteraroyl phosphatidylethanolamnine-poly(ethylenglycol-2000) and
egg yolk phosphatidylcholine. This construct solubilized 1 mg/ml
paclitaxel (P-SSMM-VIP) and retained its biophysical properties upon
lyophylization and reconstitution in saline. Moreover, it exhibited a
twofold increase in cytotoxicity to MCF-7 breast cancer cells in
comparison with P-SSMM and paclitaxel in DMSO (P < 0.05). In
addition, the construct targeted VIP receptors overexpressed in methyl
nitrosurea (MNU)-induced in situ rat breast cancer tissues. There was
a twofold increase in accumulation of intravenously administered
P-SSMM-VIP (1 mg/kg) in MNU-induced rat breast cancer, coupled
with a significantly greater regression of breast cancer in comparison
with P-SSMM and Taxol (P < 0.05). At the same time there was a
significant reduction in P-SSMM-VIP accumulation in bone marrow,
spleen and other organs in comparison with P-SSMM and Taxol
(P < 0.05). There was no significant change in systemic arterial
pressure during administration of P-SSMM-VIP. Collectively, these data
indicate that actively targeting paclitaxel passively loaded into
biocompatible, biodegradable, long-circulating SSMM to breast cancer
through VIP receptors improves drug efficacy and reduces its uptake in
injury-prone normal tissues. We suggest that P-SSMM-VIP is an
efficacious and safe, actively targeted drug delivery platform to treat
breast cancer.
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6-(1-oxobutyl)-5,8-dimetoxy-1,4-naphthoquinone
inhibits the growth of MCF-7 cells via inhibition of
angiogenesis and hypoxia inducible factor alpha
S-H Kim
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Introduction Hypoxia induces the transcription of various genes that
are involved in angiogenesis and anaerobic metabolism necessary for
the growth of tumor cells. Hypoxia-inducible factor (HIF)-1α regulates
genes that are involved in the response to hypoxia and promotes neo-
angiogenesis in cancer. Thus, 6-(1-oxobutyl)-5,8-dimetoxy-1,4-
naphthoquinone (OXO) was synthesized, to develop an anticancer
agent with antiangiogenic activity in hypoxic cancer cells.
Method The XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-
tetrazolium-5-carboxanilide) assay for cytotoxicity, ELISA ( enzyme
linked immunosorbent assay), RT-PCR and Western blotting analysis
were employed in MCF-7 human breast cancer cells under hypoxic
conditions.
Results OXO exhibited cytotoxicity against MCF-7 cells, human breast
cancer cells with an IC50 of 20 µmol/l. OXO also reduced the levels of
vascular endothelial cell growth factor (VEGF) and HIF-1α in MCF cells
exposed to hypoxia. Similarly, OXO downregulated the expression of
HIF-1 and VEGF by western blotting and RT-PCR. In addition, OXO
inhibited the basic fibroblast growth factor (bFGF) induced
proliferation, tube formation of human umbilical vein endothelial cells,
and disrupted the neovasularization in bFGF treated Matrigel in vivo.
Conclusion Taken together, OXO may exert antitumor and antiangio-
genic activity against MCF-7 cells via regulation of HIF-1α and VEGF.
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Bilateral breast cancer (BBC) is a rare clinical entity. Unlike unilateral
breast cancer there are no clear treatment guidelines for BBC. There
are several controversial issues regarding BBC pertaining to the
diagnostic criteria, nomenclature, and management policies. To address
these issues, a retrospective analysis of breast cancer database at a
tertiary care cancer center was performed and the clinical profile,
treatment patterns and outcome of patients with BBC were analyzed.
Thirty out of 1100 (2.7%) patients with breast cancer treated between
1993 and 2003 had BBC, of whom 20 patients had metachronous
and 10 patients had synchronous BBC. Family history of breast cancer
was present in five patients (16%) only. Contralateral breast cancer
(CBC) was detected mammographically in three and by clinical
examination in 27 patients. Most CBC patients had early-stage disease
compared with the index side (73% versus 27%). Fifty-six out of 60
tumors were found to be invasive ductal carcinoma, and none of the
patients had lobular carcinoma. Twenty-three patients had bilateral
mastectomy, three had unilateral mastectomy and four had a
combination of breast conservation and mastectomy. Sixteen patients
had unilateral and six had bilateral adjuvant radiotherapy. All patients
received adjuvant chemotherapy and/or hormonal therapy both for
index and CBC based on the stage and hormone receptor status. At a
median follow up of 31.5 months (3–142 months), 23 (76%) patients
were disease free and seven (24%) patients had disease relapse.
Mean overall survival of patients with MBBC was significantly longer
than those with SBBC (30.4 months versus 19.2 months; P = 0.045).
BBC is an uncommon clinical entity. These patients require
individualized treatment planning based on the tumor factors and
treatment factors of the index lesion. Optimal results can be obtained
by using a logical multimodality treatment approach for BBC.
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Introduction Postoperative irradiation of conservatively operated
breast carcinoma is one of the most common practice in radiation
oncology. In this job we analyze the acute toxicity during treatment.
Materials and method From 1999 to January 2003, 220 patients aged
31–71 (median, 55.8) with breast cancer in stage I and II after
conservative surgery were studied. Menopause was induced in 75 of the
patients with hormonal therapy. Radiation therapy of the breast after
quadrantectomy is based on the use of lateral and medial tangential
portals. With the advent of conformal 3D-treatment planning precise
physical dose localization can be achieved optimizing the dose
distribution. The definition of the volume target and the elaboration of the
treatment plan were executed on computed tomography scans. A total
dose of 50 Gy is given to the whole breast and followed by a 10 Gy
boost. In the patients  with neoplastic involvement of the lymph nodes,
chemotherapy treatment and/or endocrine therapy was instituted. The
analysis of the acute toxicity was valuated with scale EORTC RTOG.
Results and conclusion Postoperative radiotherapy was well tolerated
on its own and concomitant with chemotherapy. The cutaneous acute
toxicity in patients managed with single radiotherapy was as follows: G0
= 5.6%, G1 = 17.6%, G2 = 4.8% and G3 = 0.6%. For patients
managed with OT the cutaneous acute toxicity was as follows: G0 =
4.8%, G1 = 22.2%, G2 = 5.8% and G3 = 0.6%. For patients managed
with CT the cutaneous acute toxicity was as follows: G0 = 4.7%, G1 =
23.6%, G2 = 0.8% and G3 = 1.6%. Differences in acute cutaneous
toxicity between different outlines of CT did not emerge. Pulmonary
and/or cardiac acute reactions were not found. 
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Introduction Cancer is the second cause of mortality in Belgium and in
Hainaut. For women, breast cancer is highly prevalent (33% of
cancers). Several studies have shown that there is an increase in
certain cancers in disadvantaged populations because of risk factors
that favour the disease, and there is cancer-screening reticence in this
population. It should be noted that there is less detection breast cancer
screening in Charleroi (48% in Hainaut versus 56% in Belgium).
There are high levels of precarious lifestyle because of low level of
education, high female unemployment (33% in Charleroi versus 15% in
Belgium), and lower average income compared with the Belgian average.
Methods The project has three axes: to study the barriers and potential
levers in systematic screening; to promote awareness sessions/to
encourage underprivileged populations; and to incite GPs to promote
cancer detection screening.
Results More than 1000 women have been reached. Qualitative and
quantitative evaluation have been done for each axis. Principal barriers
for screening were fear, budget, lack of time, lack of information and
negligence. Possible levers were information, free testing, proximity of
screening centres and systematic contact with GPs. Local GPs have
been sensitized about their central role in breast cancer prevention.
Conclusion Lack of knowledge is a major barrier to breast cancer
screening. Negative consequences of breast cancer are more
important in underprivileged women, which is why our project is
pertinent and can help women not to dramatize and perhaps undertake
a screening test.
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Breast cancer is one of the most common cancers in women, and its
early detection increase the patient’s rate of survival. Several studies
have shown that computer assisted diagnosis can improve detection of
breast cancer, or at least detect those suspicious cases that are worth
studying in detail by an expert.
In this paper we analyze the performance of different neural classifiers
that are designed for identifying malignant microcalcifications on
mammograms. Specifically, we have used different techniques, such as
Multi Layer Perceptrons, Radial Basis Functions and Support Vector
Machines, comparing the capabilities of the resulting systems with
other approaches that can be found in the literature.
We have used information collected from mammograms of 210
patients in which 229 clustered microcalcifications were detected. This
information has been automatically extracted, and is related to
characteristics of the cluster and to the individual microcalcifications.
Additionally, biopsy results from each patient determined that 46% of
the cases were malignant and 54% were benign tumors.
Analysis of performance is based on receiver operating characteristic
(ROC) curves, showing that these general purpose classifiers achieve
results that are similar to those of previous automatic designs.
Hopefully, ad hoc neural designs could improve these results even
further. Finally, a comparison with the opinion of three human experts
shows that these technologies can be of great help to assist doctors in
the clinical decision process.
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A phase II randomized trial of doxorubicin (DXR) and
gemcitabine (GMZ) administered in patients with
metastatic breast cancer (MBC)
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Introduction We conducted a phase II trial to define the safety, the
efficacy, the pathological response rate and survival associated with
four cycles DXR–GMZ administered every 3 weeks followed by
surgery, then four cycles of FAC50 as a primary therapy in MBC.
Method Patients with histologically or cytologically confirmed MBC,
ECOG PS: 2 and adequate hepatic, renal and cardiac functions were
eligible. Prior chemotherapy was not allowed.
Results Fifty-one patients were included, after signing an informed
consent. Median age was 47.07 years, and 100% had stage IV. A total
of 373 cycles was administrated. Main grade 3/4 toxicities were
neutropenia in 1.1 %, anaemia in 0.5% and thrombopenia grade 2 in
1.1%. Nausea and vomiting grade 2–3 occurred in 17.4%. Regarding
efficacy, 49 out of 51 patients achieved four cycles. The overall
response rate was in 84.1%, with complete response in 58.8% and
partial response in 25.3%. Progression of disease occurred in 2.4%.
Surgery was performed in 30 patients, and 13 had histological
response (43.2%), with complete histological response in 36.6% and
partial histological response in 6.6 %. The median time to progression
was 13.3 months.
Conclusion: The combination of DXR with GMZ in MBC appears to be
an active regimen with a favourable toxicity profile. It is well tolerated
and achieved encouraging pathological response rates.
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Introduction Axillary study with ultrasound and cytological puncture
with fine needle aspirate (FNA) in patients with invasive breast cancer
is a diagnostic method included in protocols.
Method Fifty-four patients with invasive breast cancer treated in 2004
underwent axillary ultrasound and cytological puncture with fine needle
of suspicious nodes before surgery. Suspicious nodes were those with
at least one of the following signs: long-to-short axis ratio less than 1.5,
absence of hilius and cortical disruption. If the results were compatible
with metastasis then we performed axillary lymphadenectomy; if it was
found to be benign then we conducted sentinel node study.
Results In 10 patients cytological puncture with fine needle was
positive. When we conducted axillary lymphadenectomy, two patients
(20%) were found to have one positive node, one patient (10%) two
positive nodes, four patients (40%) three positive nodes, and three
patients (30%) more than three positive nodes. In the 44 patients who
had axillary ultrasound and were FNA negative, we conducted sentinel
node study: 36 patients (81.8%) were pN0i–, three (6.8%) were pN0i+,
one patient (2.2%) had a micrometastases, and three patients (9%)
had macrometastases (pN1a).
Conclusion Axillary study with ultrasound and FNA before surgery
allows excluding a group of patients to make the sentinel node.
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Introduction The c-Met protein, known as the hepatocyte growth
factor (HGF) receptor, is a transmembrane 190 kDa heterodimer with
tyrosine kinase activity, encoded by the c-met oncogene. The HGF/c-
Met signalling pathway has been shown to demonstrate various cellular
responses, including mitogenic, proliferative, morphogenic and
angiogenic activities. Although HGF and c-Met are known to be
expressed in a variety of organs and play important roles in signal
transduction, studies of its expression correlated with clinico-
pathological parameters in breast cancer are rare.
Method In this study we examined c-met mRNA and c-Met protein
expression by means of RT-PCR and immunohistochemical methods in
50 cases of invasive ductal carcinomas and 20 normal breast tissue
samples.
Results c-met mRNA amplification was detected in 35 cases (70%),
but not in normal tissues. c-Met protein overexpression was detected in
27 cases (54%) and two cases (10%), respectively. Both mRNA
amplification and protein overexpression rates were significantly higher
in tumor than in normal tissue. The c-met mRNA amplification exhibited
an increased tendency according to tumor invasiveness and nodal
metastasis. The c-Met protein overexpression was significantly
correlated with well differentiated grade and showed decreased
tendency in metastatic tumor. The concordance between both mRNA
amplification and protein expressions were not recognized.
Conclusion These results suggest that HGF/c-Met signal pathway
may be associated with breast cancer development. c-met mRNA
amplification may play an important role in tumor progression and
metastasis. c-Met protein overexpression may contribute to the
morphogenesis of well differentiated tumor.
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Introduction Metastatic breast cancer (MBC) is resistant to almost all
cytotoxic drugs and radiation, making it one of the most aggressive
malignancies in humans, with the worst mortality. The failure of tumour
cells to undergo apoptosis causes resistance to chemoradiological
therapies due to overexpression of oncogenes and transcriptionally
repressed apoptotic tumour suppressor genes due to aberrant
methylation (CIMP+). Also, upregulation of the ECM gene POEM is
associated with adhesion, migration and invasion of highly aggressive
and MBC.
Materials and method We obtained surgically a total of 168 MBC
specimens from lymph nodes and lungs of patients. Genomic DNA of
tumours was analyzed for CpG island hypermethylation by using
methylation specific PCR. All of the tumours showed hypermethylation
of tumour suppressor genes with the following frequencies: p16 89%,
RASSF1A 84%, RARb2 76%, BRCA2 54%, p53 52%, HIC1 47%,
ESR1 43%, CDH1 37% and below 35% for TRbeta1, GSTP1 and
CCND2. Quantitative IHC, WB, SB and RT-PCR revealed
overexpression of DNMT1, α8β1 integrin, bcl-2, Raf-1 and cdc25c. We
treated the MBC with anti-POEM (Arg-Gly-Asp) scFv attached onto
high-energy radioisotopes, vinorelbine-tartrate and 21-nucleotide
double-stranded siRNA segment generated against DNMT1.
Results Post-treatment, we detected re-expression of tumour
suppressor genes p53, p16, RASSF1A, RARb2, BRCA2, HIC1,
ESR1, CDH1, TRbeta1, GSTP1 and CCND2 after inhibition of
DNMT1mRNA. There was downregulation of metastatic ECM gene
POEM (Arg-Gly-Asp) due to targeted scFv blocking binding to α8β1
integrin receptor with subsequent inhibition of adhesion, spreading and
survival of metastatic tumour cells. There was inactivation of bcl-2,Raf-
1 and cdc25c due to phosphorylation by vinorelbine. Furthermore, we
detected upregulation of p21waf1, p27kip, Bid and Bak. The high
energy radioisotopes induced DNA double-strand breaks in MBC cells
and with MT depolymerizer agent vinorelbine they arrested  their
growth at the G2/M transition according to flow cytometry analysis.
We detected externalization of PS, depolarization of mitochondrial
transmembrane potential (∆ψM), activation of caspase-3, -7, -8 and -9
and bax, cleavage of poly(ADP-ribose)polymerase and DNA
fragmentation. TEM exhibited irreversible D2 apoptotic signs, forming
apoptotic bodies that were phagocytosed by adjacent tumor cells,
leading to a bystander killing effect (BKE). BrdU and MTT exhibited
inhibition of DNA synthesis and metabolic activity of treated MBC cells
compared with untreated controls.
Conclusion We were able to eradicate MBC cells with combined
chemoradioimmunotherapy after circumvention of chemoresistance
and radioresistance mechanisms such as hypermethylation of p53,
p16, RASSF1A, RARb2, BRCA2, HIC1, ESR1, CDH1, TRbeta1,
GSTP1 and CCND2, and overexpression of bcl-2, POEM, α8β1, Raf-1
and cdc25c.
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